{"key":"op_800_IL","page":{"url":"https://it.bookimed.com/clinics/country=israel/procedure=car-t-cell-therapy/","procedure":{"id":800,"slug":"car-t-cell-therapy","name":"Terapia con cellule CAR-T","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"hematology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":1,"iso":"IL","name":"Israele"},"currency":"USD","data_date":{"status":"missing","reason":"not_collected"}},"pages":{"clinics_url":"https://it.bookimed.com/clinics/country=israel/procedure=car-t-cell-therapy/","cost_url":"https://it.bookimed.com/clinics/country=israel/procedure=car-t-cell-therapy/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":84000,"to":405000,"avg":{"value":86000,"method":"median","source":"offers"},"us":{"from":420000,"to":540000},"uk":{"from":330000,"to":420000},"by_technique":[{"technique":"Autologous CD19-directed CAR T-cell therapy","technique_id":"autologous-cd19-directed-car","price_from":150000,"currency":"USD","source":"estimate","date":"2026-11-17"},{"technique":"Autologous BCMA-directed CAR T-cell therapy","technique_id":"autologous-bcma-directed-car","price_from":86000,"currency":"USD","source":"package","offers":2,"date":"2026-11-17"}],"by_city":[{"city":"Ramat Gan","from":84000},{"city":"Gerusalemme","from":195000},{"city":"Tel Aviv-Giaffa","from":180000}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"source":"offers","items":[{"tier":"standard","min":85000,"max":89400,"median":86000,"count":3},{"tier":"premium","min":84000,"max":86300,"median":86000,"count":10}]},"comparison":[{"country_iso":"UA","from":90000,"to":150000},{"country_iso":"FR","from":295000,"to":385000},{"country_iso":"GB","from":330000,"to":420000},{"country_iso":"US","from":420000,"to":540000},{"country_iso":"TR","from":150000,"to":220000},{"country_iso":"MX","from":120000,"to":185000},{"country_iso":"DE","from":285000,"to":365000},{"country_iso":"CA","from":340000,"to":470000},{"country_iso":"AE","from":190000,"to":310000},{"country_iso":"TH","from":150000,"to":220000},{"country_iso":"PL","from":165000,"to":230000},{"country_iso":"KR","from":220000,"to":300000},{"country_iso":"CZ","from":150000,"to":195000},{"country_iso":"AT","from":280000,"to":365000},{"country_iso":"ES","from":380000,"to":520000},{"country_iso":"IT","from":400000,"to":650000},{"country_iso":"CN","from":275000,"to":319000},{"country_iso":"AU","from":330000,"to":420000},{"country_iso":"IN","from":38000,"to":70000},{"country_iso":"MY","from":120000,"to":180000},{"country_iso":"VN","from":150000,"to":230000},{"country_iso":"BR","from":280000,"to":400000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":80,"variant":">=15%"},"package":{"included":["Consultation with a hematologist","Consultation with an oncologist","24-hr nurse services","3 meals per day by nutritionist","Blood tests","Complete blood count with cancer markers and a proteinogram","Сonsultation with an oncohematologist","Biochemistry blood test","Biopsy","Electrocardiogram (ECG)","Transfer airport-clinic-airport","Consultation with a pediatric hematologist","Consultation with an immunologist","Hospitalization","PET/CT","CT Scan","CT angiography","Echocardiography","Head MRI","Anti-HBC test","Anti-HCVAb test","Anti-HIV test","Chest X-ray","Consultation with a cardiologist","Consultation with a pediatrician","Follow-up examination","Complete blood count (CBC)","Consultation with a doctor","Consultation with a neurologist","Ultrasound","Consultation of a radiologist","Follow-up visit","Post-operative care","Preoperative tests","Transfer airport-hotel-airport","Ultrasonography (USG)","Color doppler echocardiography","Consultation with a surgeon","Ultrasonography","Ultrasound biomicroscopy (UBM)"],"excluded":["Accommodation is not included"],"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":3,"items":[{"id":1,"name":"Sourasky Medical Center (Ichilov)","city":"Tel Aviv","rating":4.5,"reviews_count":172,"accreditations":["World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2021 by Newsweek","World's Best Hospitals 2020 by Newsweek","Patient choice for Check-up","Fastest treatment organization","Joint Commission International","World's Best Specialized Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek","World's Best Hospitals 2022 by Newsweek"],"rank":1,"has_procedure":true,"why_ranked":"Offers CAR T-cell therapy with success rates up to 90% for blood cancers. Performs 3,500+ hematology procedures annually and includes onco-hematology specialists.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":9,"name":"Sheba Medical Center","city":"Ramat Gan","rating":5,"reviews_count":2,"accreditations":["Best Maternity Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2021 by Newsweek","World's Best Hospitals 2020 by Newsweek","Joint Commission International","International Organization for Standardization","World's Best Specialized Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek","World's Best Hospitals 2022 by Newsweek","World's Best Hospitals 2026 by Newsweek","World's Best Hospitals 2025 by Newsweek"],"rank":2,"has_procedure":true,"why_ranked":"On-site GMP cell manufacturing with fresh, non-cryopreserved cells. 500+ patients treated including 110+ children, with ~80% remission in pediatric ALL and >50% response in aggressive lymphomas.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":[{"id":"69e977f7da8c9f6c5e094652","price":84000,"nights":20,"included":["3 meals per day by nutritionist","24-hr nurse services","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Burkitt Lymphoma At Sheba Medical Center, children and young patients with Burkitt lymphoma have access to one of the most advanced and trusted CAR-T therapy programs in the world. This highly aggressive form of lymphoma requires rapid, precise treatment, especially in relapsed or treatment-resistant cases where CAR-T therapy offers a powerful, personalized option. A Personalized Treatment Designed for Each Child CAR-T therapy uses the patient’s own immune system to recognize and eliminate cancer cells. For children with Burkitt lymphoma, this innovative approach can provide new hope when conventional therapies are no longer effective. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target lymphoma Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body and offering the potential for durable remission. Expert Pediatric Leadership and Care The program is led by Prof. Amos Toren, a world-recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and more than 1,500 bone marrow transplants performed. Children are cared for within a dedicated pediatric environment that includes: Specialized pediatric CAR-T units with 24/7 monitoring A multidisciplinary team of experts in hematology, oncology, and immunology A family-centered approach, focused on comfort, safety, and support Full international patient services, including travel and care coordination Proven Expertise in Complex Cases Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The team has extensive experience treating high-risk and aggressive lymphomas, including Burkitt lymphoma, offering advanced options when other treatments have limited success. Comprehensive Evaluation and Support Each child undergoes a full diagnostic work-up before treatment, including: advanced imaging, bone marrow evaluation, genetic and molecular testing, and cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed throughout the entire process. A Trusted Place for Advanced Pediatric Cancer Care By combining rapid access to treatment, leading medical expertise, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Burkitt lymphoma with CAR-T therapy focused on achieving remission and helping children return to a healthy and active life."},{"id":"69e97a65a3ddb2d98d067d36","price":89400,"nights":21,"included":["Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Sheba Pediatric CAR-T Program for Multiple Myeloma At Sheba Medical Center, children and young patients with multiple myeloma have access to one of the most advanced and trusted CAR-T therapy programs in the world. While multiple myeloma is more common in adults, Sheba provides highly specialized care for young and complex cases, including relapsed or treatment-resistant disease. A Personalized Treatment Designed for Each Patient CAR-T therapy uses the patient’s own immune system to recognize and destroy cancer cells. For patients with multiple myeloma, this innovative approach offers a highly targeted option when standard treatments are no longer effective. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target myeloma cells Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T functions as a “living therapy,” continuing to work in the body and offering the potential for long-term disease control and remission. Expert Pediatric Leadership and Care The program is led by Prof. Amos Toren, a globally recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed. Patients are treated within a highly specialized environment that includes: Dedicated pediatric and young adult CAR-T units with 24/7 monitoring A multidisciplinary team of hemato-oncologists, immunologists, and supportive care specialists A patient- and family-centered approach, ensuring comfort and continuous support Full international patient services, including travel and care coordination Advanced Expertise in Complex Cases Sheba is a global leader in CAR-T therapy, with strong clinical outcomes across hematologic cancers The program is experienced in managing rare, complex, and high-risk myeloma cases, offering advanced treatment options when other therapies have been exhausted. Comprehensive Evaluation and Ongoing Support Each patient undergoes a detailed diagnostic evaluation, including: advanced imaging, bone marrow testing, genetic and molecular profiling, and full cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring clear communication and a supportive experience for international families. A Trusted Place for Advanced Care By combining cutting-edge science, rapid access to therapy, and compassionate care, Sheba offers one of the most advanced CAR-T programs for multiple myeloma focused on improving outcomes and helping patients return to a better quality of life."},{"id":"69e97c3ca3ddb2d98d067d37","price":86000,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Primary CNS Lymphoma At Sheba Medical Center, children and young patients with primary central nervous system (CNS) lymphoma have access to one of the most advanced and specialized CAR-T therapy programs in the world. This rare and complex lymphoma, affecting the brain and spinal cord, requires highly precise and coordinated care, especially in relapsed or treatment-resistant cases. A Personalized Treatment Designed for Each Patient CAR-T therapy uses the patient’s own immune system to recognize and destroy cancer cells. For CNS lymphoma, this innovative approach offers a targeted option when conventional therapies are no longer sufficient. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target lymphoma cells Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body and offering the potential for long-term disease control. Expert Pediatric Leadership and Multidisciplinary Care The program is led by Prof. Amos Toren, a globally recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed. Given the complexity of CNS lymphoma, care is delivered through a multidisciplinary team, including pediatric hemato-oncologists, neurologists, neurosurgeons, and radiology experts. The program includes: Specialized pediatric CAR-T units with 24/7 monitoring Advanced neuro-imaging and precision diagnostics A supportive, family-centered environment Full international patient services, including travel and care coordination Proven Expertise in Complex and High-Risk Cases Sheba is a global leader in CAR-T therapy, with strong outcomes across hematologic cancers: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The team has extensive experience in treating rare and high-risk conditions, including CNS involvement, offering advanced options when other treatments are limited. Comprehensive Evaluation and Ongoing Support Each patient undergoes a full diagnostic work-up, including: advanced brain and spinal imaging (MRI/CT), bone marrow evaluation, genetic and molecular testing, and cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed throughout the entire journey. A Trusted Place for Advanced Pediatric Neuro-Oncology Care By combining cutting-edge immunotherapy, neurological expertise, and compassionate care, Sheba provides one of the most advanced environments for treating primary CNS lymphoma with CAR-T focused on achieving the best possible outcomes and quality of life for every patient."},{"id":"69e92f00d98e30671b08f193","price":86000,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Head MRI","Color doppler echocardiography","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-hotel-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Leukemia (ALL & AML) At Sheba Medical Center, children and young patients with leukemia have access to one of the most advanced and trusted CAR-T therapy programs in the world. The program specializes in treating acute lymphoblastic leukemia (ALL) and Acute Myeloid Leukemia (AML), including relapsed or treatment-resistant cases using highly personalized immunotherapy. A Personalized Treatment Designed for Each Patient CAR-T therapy uses the patient’s own immune system to recognize and destroy leukemia cells. This approach is especially important for patients who have not responded to standard treatments. At Sheba, the entire process is performed on-site, ensuring speed and optimal quality: Apheresis – collection of immune (T) cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target leukemia Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body over time. Expert Care in a Supportive Environment Patients are treated by leading hemato-oncology specialists, under the supervision of Prof. Amos Toren, within dedicated CAR-T units. The program provides: Specialized pediatric and young adult CAR-T care with 24/7 monitoring A multidisciplinary team (hematology, oncology, immunology) A supportive, patient- and family-centered environment Full international patient services, including travel and care coordination Proven Outcomes and Global Leadership Sheba is a global leader in CAR-T therapy, with strong clinical outcomes: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The program is experienced in treating complex and high-risk leukemia cases, offering options when other treatments are limited. Comprehensive Evaluation and Ongoing Support Each patient undergoes a full diagnostic work-up, including: advanced imaging, bone marrow biopsy, genetic and molecular testing, as well as cardiac and pulmonary evaluation. Care is provided in English, Russian, and Arabic, ensuring clear communication and continuous support for international families. A Place Patients and Families Can Trust By combining advanced science, rapid access to treatment, and compassionate care, Sheba offers one of the most trusted CAR-T programs for leukemia focused on achieving remission and helping patients return to a healthy, active life."},{"id":"69e975cfb046df7de7039a02","price":84200,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Biochemistry blood test","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Non-Hodgkin Lymphomas (DLBCL, FL, MCL) At Sheba Medical Center, children and young patients with Non-Hodgkin lymphomas have access to one of the most advanced and trusted CAR-T therapy programs in the world. The program focuses on treating diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL), especially in relapsed or treatment-resistant cases using highly personalized immunotherapy. A Personalized Treatment Designed for Each Child CAR-T therapy uses the patient’s own immune system to identify and destroy cancer cells. This approach offers new hope for children and young patients when standard therapies are no longer effective. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target lymphoma Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T functions as a “living therapy,” continuing to work in the body over time and offering the potential for long-term remission. Expert Pediatric Leadership and Care The pediatric CAR-T program is led by Prof. Amos Toren, one of the most experienced specialists in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed. The program includes: Dedicated pediatric CAR-T units with 24/7 expert monitoring A multidisciplinary team of hemato-oncologists, immunologists, and pediatric specialists A supportive, family-centered environment designed for children Full international patient support, including travel and care coordination Proven Outcomes and Global Expertise Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The program is highly experienced in treating complex and high-risk lymphoma cases, offering advanced options when other treatments have been exhausted. Comprehensive Evaluation and Support Each child undergoes a thorough diagnostic evaluation, including: advanced imaging, bone marrow testing, genetic and molecular profiling, and full cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed at every stage. A Trusted Place for Advanced Pediatric Cancer Care By combining cutting-edge science, rapid access to treatment, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Non-Hodgkin lymphomas with CAR-T therapy focused on achieving remission and helping children return to a healthy, active life."},{"id":"69e932dc18284bfa1d0a0d02","price":86000,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","Consultation with an oncologist","Consultation with a hematologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-hotel-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric Personalized CAR-T Immunotherapy Program for Blood Cancers At Sheba Medical Center, children and young patients receive some of the most advanced and compassionate cancer care available today. Sheba is a global leader in pediatric CAR-T cell therapy, offering highly personalized treatment for complex and resistant blood cancers, including: • Acute lymphoblastic leukemia (ALL) and Acute Myeloid Leukemia (AML) • Non-Hodgkin lymphomas (DLBCL, FL, MCL) • Burkitt lymphoma • CLL / Richter’s transformation • Primary CNS lymphoma • Multiple myeloma A Gentle, Fully Integrated CAR-T Journey Every step of the CAR-T process is performed on-site at Sheba, ensuring speed, safety, and the highest quality of care, especially important for children. The treatment includes three carefully coordinated stages: • Apheresis – collecting the child’s own immune (T) cells • Cell Engineering – reprogramming the cells at Sheba’s Advanced Biotherapy Center • Infusion – returning the cells to fight the cancer Because everything is done within the hospital, treatment can begin quickly and is typically completed within ~10 days. CAR-T works as a “living therapy,” continuing to act in the body and offering the potential for long-term remission. All patients are treated under the guidance of leading experts, including Prof. Amos Toren, with dedicated pediatric CAR-T teams ensuring continuous monitoring and care. Designed Especially for Children and Families Sheba understands that treating a child means caring for the entire family. The pediatric program offers: • Specialized pediatric CAR-T units with 24/7 expert monitoring • A multidisciplinary team of hemato-oncologists, immunologists, and pediatric specialists • A supportive, child-friendly environment focused on comfort and safety • Full international patient support, including travel and care coordination Clinical Excellence You Can Trust Sheba is one of the world’s leading centers in pediatric CAR-T, with strong clinical outcomes: • ~90% remission in pediatric patients • ~80% in young adults (up to 23 years) • ~70% in adults Importantly, Sheba offers flexibility in age criteria, ensuring that children and young patients can access advanced therapies when needed. Comprehensive Care from Start to Finish Each child receives a complete evaluation before treatment, including: advanced imaging, bone marrow testing, genetic and molecular analysis, and full cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, helping families feel supported and informed throughout the entire journey. Why Families Choose Sheba By combining advanced science, speed, and deeply personalized care, Sheba provides one of the most trusted pediatric CAR-T programs in the world focused not only on treating disease, but on giving children the best possible chance to return to a healthy, active life."},{"id":"69d6029bedb8b85c1a0bd0e2","price":86000,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Blood tests","Follow-up examination","Ultrasound","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Multiple Myeloma at Sheba Medical Center For patients diagnosed with Multiple Myeloma, especially those with relapsed or treatment-resistant disease, access to advanced therapies can significantly change outcomes. Sheba Medical Center, one of the world’s leading hospitals, offers state-of-the-art CAR-T cell therapy, providing new hope when standard treatments are no longer effective. Sheba combines innovative immunotherapy, extensive clinical experience, and rapid access to treatment to deliver highly personalized care for complex myeloma cases. A Faster Path to Advanced Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality what is a key advantage for patients requiring timely intervention. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to recognize and destroy myeloma cells By avoiding external laboratories, treatment can begin in approximately 10 days, significantly reducing waiting time compared to many international centers. CAR-T therapy acts as a “living therapy,” continuing to function within the body and offering the potential for deep and durable remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. A Powerful Option for Advanced Myeloma Multiple Myeloma often requires multiple lines of therapy over time. At Sheba, hematologists, oncologists, and immunotherapy specialists work together to develop a personalized treatment strategy, especially for patients who have exhausted conventional options. CAR-T therapy has shown promising and durable responses in advanced myeloma, offering a new therapeutic pathway where alternatives may be limited. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – one of the leading CAR-T programs in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary expertise – integrated care across specialties • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a complete diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and full medical assessment, ensuring a precise, individualized treatment plan. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. A Leading Center for Advanced Myeloma Treatment By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for Multiple Myeloma worldwide offering patients a real opportunity for long-term disease control and improved quality of life."},{"id":"69d5fbe0fe4c90900e071d75","price":86000,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Blood tests","Follow-up examination","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a pediatric hematologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"CAR-T Therapy for Burkitt Lymphoma at Sheba Medical Center For patients diagnosed with Burkitt Lymphoma, one of the most aggressive and fast-growing types of lymphoma, timing and access to advanced treatment are critical. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease. Sheba combines rapid treatment access, cutting-edge immunotherapy, and extensive clinical expertise to manage even the most challenging and fast-progressing cases. A Faster Path to Life-Saving Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality essential for aggressive diseases like Burkitt Lymphoma. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to rapidly target and destroy lymphoma cells By eliminating the need for external laboratories, treatment can begin in approximately 10 days, significantly reducing delays compared to many international centers. CAR-T therapy acts as a “living therapy,” continuing to work in the body and offering the potential for rapid and durable remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Advanced Treatment for Aggressive Disease Burkitt Lymphoma requires immediate and highly specialized care. At Sheba, hematologists, oncologists, and immunotherapy experts work together to design a personalized treatment strategy, tailored to the urgency and biology of each case. CAR-T therapy offers a powerful option for patients who have exhausted standard treatments, providing meaningful responses even in highly aggressive disease settings. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – leading CAR-T program in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary expertise – integrated care across specialties • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise and individualized treatment plan. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. A Leading Center for Advanced Lymphoma Care By combining speed, innovation, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for Burkitt Lymphoma worldwide offering patients a real chance for remission and improved survival in one of the most aggressive cancers."},{"id":"69d5ae553eb001ab1907ddb2","price":85000,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Ultrasonography (USG)","Electrocardiogram (ECG)","Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for CLL / Richter’s Transformation at Sheba Medical Center For patients diagnosed with Chronic Lymphocytic Leukemia (CLL) or Richter’s Transformation, a more aggressive progression of the disease, finding an effective treatment option can be especially challenging. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease. Sheba combines cutting-edge immunotherapy with deep expertise in complex hematologic cancers, delivering personalized solutions even in the most aggressive cases. A Faster Path to Advanced Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, a critical advantage for patients with rapidly progressing disease. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to identify and destroy cancer cells By eliminating the need for external laboratories, treatment can begin in approximately 10 days, significantly reducing delays compared to many international centers. CAR-T therapy acts as a “living therapy,” continuing to work in the body and offering the potential for deep and durable remission, even in aggressive disease forms like Richter’s transformation. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Advanced Treatment for Complex Cases CLL and Richter’s transformation often require highly specialized care. At Sheba, hematologists, oncologists, and immunotherapy experts work together to design the most effective, individualized treatment strategy. CAR-T therapy provides a promising option for patients who have exhausted conventional therapies, offering meaningful clinical responses and improved outcomes in difficult-to-treat cases. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – one of the leading CAR-T programs in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary expertise – integrated care across specialties • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a complete diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and full medical assessment, ensuring a precise, personalized treatment plan. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. A Leading Center for Advanced Hemato-Oncology Care By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for CLL and Richter’s transformation worldwide offering patients a real opportunity for disease control and improved quality of life."},{"id":"69d5ab7cc88c3f9bfe0451b2","price":85300,"nights":21,"included":["Post-operative care","3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Preoperative tests","Blood tests","Follow-up examination","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a pediatric hematologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center For patients diagnosed with Acute Lymphoblastic Leukemia (ALL), especially those with relapsed or treatment-resistant disease, access to advanced therapy can be life-changing. Sheba Medical Center, ranked among the World's Top 10 Hospitals by Newsweek 2026, offers state-of-the-art CAR-T cell therapy, providing new hope where conventional treatments may no longer be effective. Sheba Medical Center is internationally recognized for its expertise in advanced cellular therapies, including CAR-T therapy for ALL, particularly in pediatric and young adult patients, combining cutting-edge science with extensive clinical experience. A Faster Path to Life-Saving Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, critical in fast-progressing diseases like ALL. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to target and eliminate leukemia cells By keeping the entire process in-house, treatment can begin in approximately 10 days, significantly faster than many international centers. CAR-T therapy acts as a “living drug,” continuing to work in the body and offering the potential for deep and lasting remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Outstanding Outcomes That Offer Real Hope These outcomes provide a powerful treatment option and a second chance for patients with limited alternatives. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – leading CAR-T program in the region • Dedicated CAR-T units – specialized care with 24/7 monitoring • Multidisciplinary expertise – hematology, oncology, and immunotherapy teams working together • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise, individualized treatment plan. Services are available in English, Russian, and Arabic, providing a seamless experience for international patients and their families. By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for ALL worldwide, offering patients not just treatment, but a real opportunity for remission and renewed life."},{"id":"69d5a663ac1ed88d6d0521f2","price":86300,"nights":21,"included":["Post-operative care","3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Preoperative tests","Blood tests","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with a surgeon","Consultation with a neurologist","Consultation of a radiologist","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Primary CNS Lymphoma at Sheba Medical Center For patients diagnosed with Primary central nervous system Lymphoma (PCNSL), a rare and complex cancer affecting the brain and central nervous system, choosing the right treatment center is critical. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease. Sheba combines cutting-edge immunotherapy with deep expertise in neuro-oncology, delivering highly personalized care for even the most challenging cases. A Faster Path to Advanced Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality crucial for patients with aggressive CNS disease. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reintroduction of modified cells designed to target lymphoma cells, including those within the central nervous system By avoiding external laboratories, treatment can begin in approximately 10 days, significantly reducing delays and allowing faster access to life-saving therapy. CAR-T acts as a “living therapy,” continuing to work inside the body and offering the potential for long-term disease control and remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Proven Expertise in Complex Cases Primary CNS lymphoma requires a highly specialized, multidisciplinary approach. At Sheba, hematologists, neuro-oncologists, neurologists, and imaging specialists work together to design the most effective treatment strategy for each patient. CAR-T therapy offers a promising option for patients who have exhausted conventional treatments, with encouraging remission outcomes even in advanced cases. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – leading CAR-T program in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary CNS expertise – integrated hematology and neuro-oncology care • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a full evaluation, including advanced brain imaging (MRI/CT), molecular and genetic testing, and complete medical assessment, ensuring a precise and individualized treatment plan. Services are available in English, Russian, and Arabic, providing a smooth and supportive experience for international patients. A Leading Center for Advanced Neuro-Oncology Care By combining innovative CAR-T technology, in-house cell production, and multidisciplinary expertise, Sheba offers one of the most advanced treatment options for Primary CNS Lymphoma worldwide giving patients access to therapies that can extend survival and improve quality of life."},{"id":"69cedd2f69a067457406e684","price":86000,"nights":21,"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Blood tests","Follow-up examination","Ultrasound","Echocardiography","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Follow-up visit","Consultation with an immunologist","Consultation with a neurologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Сonsultation with an oncohematologist","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Non-Hodgkin Lymphomas (DLBCL, FL, MCL) at Sheba Medical Center For patients facing relapsed or resistant Non-Hodgkin lymphoma, finding the right treatment center can make a life-changing difference. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope when standard treatments are no longer effective. Sheba specializes in treating DLBCL, Follicular Lymphoma (FL), and Mantle Cell Lymphoma (MCL) with a highly personalized approach, combining cutting-edge science, speed, and clinical expertise. A Faster Path to Treatment When Time Matters Most At Sheba, the entire CAR-T process is performed on-site, without delays caused by external laboratories. • T-cells are collected (apheresis) • Genetically engineered at Sheba’s Advanced Biotherapy Center • Reinfused to target and destroy lymphoma cells This streamlined approach allows treatment to begin in approximately 10 days, significantly faster than many international centers. CAR-T therapy acts as a “living drug”, continuing to work inside the body and offering the potential for long-term remission. All patients are treated under the leadership of Prof. Arnon Nagler, a world-renowned expert in hemato-oncology. Proven Results That Offer Real Hope Even in complex and advanced cases, CAR-T therapy at Sheba has demonstrated high remission rates • Up to 90% in pediatric patients These outcomes provide a meaningful second chance for patients who have exhausted other options. Why Patients Choose Sheba • Rapid access to treatment – no waiting weeks for cell production • Extensive experience – one of the largest CAR-T programs in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary care – leading specialists working together on every case • Full international support – from medical review to travel and coordination Comprehensive, Personalized Care Each patient undergoes a complete evaluation, including advanced imaging, genetic and molecular testing, and full medical assessment, ensuring the most effective, tailored treatment plan. Services are available in English, Russian, and Arabic, making the experience smooth and supportive for international patients. A Global Leader in Advanced Cancer Care By combining speed, innovation, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for lymphoma patients worldwide, offering not just treatment, but a real opportunity for remission and renewed quality of life."},{"id":"69ced4fb69a067457406e683","price":85000,"nights":21,"included":["Ultrasound biomicroscopy (UBM)","3 meals per day by nutritionist","24-hr nurse services","CT Scan","Ultrasonography (USG)","Blood tests","Follow-up examination","Ultrasound","Ultrasonography","Complete blood count (CBC)","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Follow-up visit","Consultation with an immunologist","Consultation with a neurologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation of a radiologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"CAR-T Therapy at Sheba Medical Center Sheba Medical Center is high expertised in CAR-T cell therapy, offering advanced, personalized treatment for a wide range of hematologic cancers, including: Non-Hodgkin lymphomas (DLBCL, FL, MCL), primary CNS lymphoma, ALL, CLL/Richter’s transformation, Burkitt lymphoma, and multiple myeloma. A Fast, Fully Integrated CAR-T Process At Sheba, the entire CAR-T procedure is performed on-site, ensuring speed, precision, and optimal cell quality. The process includes three key steps: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at the Advanced Biotherapy Center Infusion – reintroduction of modified cells to target cancer Unlike many centers, Sheba does not send cells abroad. This allows treatment to be completed in approximately 10 days, making CAR-T a true “living drug” capable of long-term remission. All patients are evaluated and treated under the supervision of Prof. Arnon Nagler, a leading expert in hemato-oncology. Why Choose Sheba for CAR-T Rapid access – on-site production reduces waiting time from weeks to ~10 days Extensive experience – largest CAR-T program in Israel and the region Dedicated CAR-T units – for both adults and children, with 24/7 monitoring Multidisciplinary care – hematology, oncology, immunology experts working together Global patient services – full support with medical coordination and travel logistics Clinical Excellence & Outcomes Sheba is a global leader in pediatric CAR-T, with no strict age limitations for pediatric patients. Reported outcomes show: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults Comprehensive Evaluation & Support Each patient undergoes a thorough diagnostic work-up, including: physician consultations, advanced imaging (CT, ultrasound, nuclear medicine), bone marrow biopsy, genetic and molecular testing (FISH, karyotyping), cardiac and pulmonary evaluation, and laboratory testing. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. Key Advantage By combining in-house cell manufacturing, leading expertise, and integrated care, Sheba delivers one of the fastest, most advanced, and most personalized CAR-T programs."}]},{"id":16,"name":"Hadassah Medical Center","city":"Jerusalem","rating":4.2,"reviews_count":13,"accreditations":["Nobel Peace Prize","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":3,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":16,"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":5,"slug":"ramat-gan","name":"Ramat Gan","clinics_count":1,"price_from":84000,"profile":{"city_type":"City east of Tel Aviv, Israel","access":["Ben Gurion Airport (TLV), 20 km from Tel Aviv"],"sources":["https://en.wikipedia.org/wiki/Ramat_Gan","https://en.wikipedia.org/wiki/Ben_Gurion_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":3,"slug":"jerusalem","name":"Gerusalemme","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":195000,"profile":{"city_type":"Historic city in the Judaean Mountains","access":["Ben Gurion Airport (TLV), 45 km from Jerusalem"],"sources":["https://en.wikipedia.org/wiki/Jerusalem","https://en.wikipedia.org/wiki/Ben_Gurion_Airport"],"checked_at":"2026-11-03","status":"ok"}},{"id":2,"slug":"tel-aviv","name":"Tel Aviv-Giaffa","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":180000,"profile":{"city_type":"Mediterranean coastal economic and tech hub","access":["Ben Gurion Airport (TLV), 20 km southeast of city"],"sources":["https://en.wikipedia.org/wiki/Tel_Aviv","https://en.wikipedia.org/wiki/Ben_Gurion_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":13,"active_with_related":13,"hospital_nights_median":21,"days_in_country_median":{"status":"missing","reason":"fewer than 10 offers with hotel days"},"top_offers":[{"id":"69e977f7da8c9f6c5e094652","clinic_id":9,"clinic_listed":true,"price":84000,"nights":20,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Burkitt Lymphoma At Sheba Medical Center, children and young patients with Burkitt lymphoma have access to one of the most advanced and trusted CAR-T therapy programs in the world. This highly aggressive form of lymphoma requires rapid, precise treatment, especially in relapsed or treatment-resistant cases where CAR-T therapy offers a powerful, personalized option. A Personalized Treatment Designed for Each Child CAR-T therapy uses the patient’s own immune system to recognize and eliminate cancer cells. For children with Burkitt lymphoma, this innovative approach can provide new hope when conventional therapies are no longer effective. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target lymphoma Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body and offering the potential for durable remission. Expert Pediatric Leadership and Care The program is led by Prof. Amos Toren, a world-recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and more than 1,500 bone marrow transplants performed. Children are cared for within a dedicated pediatric environment that includes: Specialized pediatric CAR-T units with 24/7 monitoring A multidisciplinary team of experts in hematology, oncology, and immunology A family-centered approach, focused on comfort, safety, and support Full international patient services, including travel and care coordination Proven Expertise in Complex Cases Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The team has extensive experience treating high-risk and aggressive lymphomas, including Burkitt lymphoma, offering advanced options when other treatments have limited success. Comprehensive Evaluation and Support Each child undergoes a full diagnostic work-up before treatment, including: advanced imaging, bone marrow evaluation, genetic and molecular testing, and cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed throughout the entire process. A Trusted Place for Advanced Pediatric Cancer Care By combining rapid access to treatment, leading medical expertise, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Burkitt lymphoma with CAR-T therapy focused on achieving remission and helping children return to a healthy and active life.","is_package":true}],"packages":[{"id":"69e977f7da8c9f6c5e094652","clinic_id":9,"clinic_listed":true,"price":84000,"nights":20,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Burkitt Lymphoma At Sheba Medical Center, children and young patients with Burkitt lymphoma have access to one of the most advanced and trusted CAR-T therapy programs in the world. This highly aggressive form of lymphoma requires rapid, precise treatment, especially in relapsed or treatment-resistant cases where CAR-T therapy offers a powerful, personalized option. A Personalized Treatment Designed for Each Child CAR-T therapy uses the patient’s own immune system to recognize and eliminate cancer cells. For children with Burkitt lymphoma, this innovative approach can provide new hope when conventional therapies are no longer effective. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target lymphoma Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body and offering the potential for durable remission. Expert Pediatric Leadership and Care The program is led by Prof. Amos Toren, a world-recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and more than 1,500 bone marrow transplants performed. Children are cared for within a dedicated pediatric environment that includes: Specialized pediatric CAR-T units with 24/7 monitoring A multidisciplinary team of experts in hematology, oncology, and immunology A family-centered approach, focused on comfort, safety, and support Full international patient services, including travel and care coordination Proven Expertise in Complex Cases Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The team has extensive experience treating high-risk and aggressive lymphomas, including Burkitt lymphoma, offering advanced options when other treatments have limited success. Comprehensive Evaluation and Support Each child undergoes a full diagnostic work-up before treatment, including: advanced imaging, bone marrow evaluation, genetic and molecular testing, and cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed throughout the entire process. A Trusted Place for Advanced Pediatric Cancer Care By combining rapid access to treatment, leading medical expertise, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Burkitt lymphoma with CAR-T therapy focused on achieving remission and helping children return to a healthy and active life.","is_package":true},{"id":"69e97a65a3ddb2d98d067d36","clinic_id":9,"clinic_listed":true,"price":89400,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"Sheba Pediatric CAR-T Program for Multiple Myeloma At Sheba Medical Center, children and young patients with multiple myeloma have access to one of the most advanced and trusted CAR-T therapy programs in the world. While multiple myeloma is more common in adults, Sheba provides highly specialized care for young and complex cases, including relapsed or treatment-resistant disease. A Personalized Treatment Designed for Each Patient CAR-T therapy uses the patient’s own immune system to recognize and destroy cancer cells. For patients with multiple myeloma, this innovative approach offers a highly targeted option when standard treatments are no longer effective. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target myeloma cells Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T functions as a “living therapy,” continuing to work in the body and offering the potential for long-term disease control and remission. Expert Pediatric Leadership and Care The program is led by Prof. Amos Toren, a globally recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed. Patients are treated within a highly specialized environment that includes: Dedicated pediatric and young adult CAR-T units with 24/7 monitoring A multidisciplinary team of hemato-oncologists, immunologists, and supportive care specialists A patient- and family-centered approach, ensuring comfort and continuous support Full international patient services, including travel and care coordination Advanced Expertise in Complex Cases Sheba is a global leader in CAR-T therapy, with strong clinical outcomes across hematologic cancers The program is experienced in managing rare, complex, and high-risk myeloma cases, offering advanced treatment options when other therapies have been exhausted. Comprehensive Evaluation and Ongoing Support Each patient undergoes a detailed diagnostic evaluation, including: advanced imaging, bone marrow testing, genetic and molecular profiling, and full cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring clear communication and a supportive experience for international families. A Trusted Place for Advanced Care By combining cutting-edge science, rapid access to therapy, and compassionate care, Sheba offers one of the most advanced CAR-T programs for multiple myeloma focused on improving outcomes and helping patients return to a better quality of life.","is_package":true},{"id":"69e97c3ca3ddb2d98d067d37","clinic_id":9,"clinic_listed":true,"price":86000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Primary CNS Lymphoma At Sheba Medical Center, children and young patients with primary central nervous system (CNS) lymphoma have access to one of the most advanced and specialized CAR-T therapy programs in the world. This rare and complex lymphoma, affecting the brain and spinal cord, requires highly precise and coordinated care, especially in relapsed or treatment-resistant cases. A Personalized Treatment Designed for Each Patient CAR-T therapy uses the patient’s own immune system to recognize and destroy cancer cells. For CNS lymphoma, this innovative approach offers a targeted option when conventional therapies are no longer sufficient. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target lymphoma cells Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body and offering the potential for long-term disease control. Expert Pediatric Leadership and Multidisciplinary Care The program is led by Prof. Amos Toren, a globally recognized expert in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed. Given the complexity of CNS lymphoma, care is delivered through a multidisciplinary team, including pediatric hemato-oncologists, neurologists, neurosurgeons, and radiology experts. The program includes: Specialized pediatric CAR-T units with 24/7 monitoring Advanced neuro-imaging and precision diagnostics A supportive, family-centered environment Full international patient services, including travel and care coordination Proven Expertise in Complex and High-Risk Cases Sheba is a global leader in CAR-T therapy, with strong outcomes across hematologic cancers: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The team has extensive experience in treating rare and high-risk conditions, including CNS involvement, offering advanced options when other treatments are limited. Comprehensive Evaluation and Ongoing Support Each patient undergoes a full diagnostic work-up, including: advanced brain and spinal imaging (MRI/CT), bone marrow evaluation, genetic and molecular testing, and cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed throughout the entire journey. A Trusted Place for Advanced Pediatric Neuro-Oncology Care By combining cutting-edge immunotherapy, neurological expertise, and compassionate care, Sheba provides one of the most advanced environments for treating primary CNS lymphoma with CAR-T focused on achieving the best possible outcomes and quality of life for every patient.","is_package":true},{"id":"69e92f00d98e30671b08f193","clinic_id":9,"clinic_listed":true,"price":86000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Head MRI","Color doppler echocardiography","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-hotel-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Leukemia (ALL & AML) At Sheba Medical Center, children and young patients with leukemia have access to one of the most advanced and trusted CAR-T therapy programs in the world. The program specializes in treating acute lymphoblastic leukemia (ALL) and Acute Myeloid Leukemia (AML), including relapsed or treatment-resistant cases using highly personalized immunotherapy. A Personalized Treatment Designed for Each Patient CAR-T therapy uses the patient’s own immune system to recognize and destroy leukemia cells. This approach is especially important for patients who have not responded to standard treatments. At Sheba, the entire process is performed on-site, ensuring speed and optimal quality: Apheresis – collection of immune (T) cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target leukemia Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T acts as a “living therapy,” continuing to work in the body over time. Expert Care in a Supportive Environment Patients are treated by leading hemato-oncology specialists, under the supervision of Prof. Amos Toren, within dedicated CAR-T units. The program provides: Specialized pediatric and young adult CAR-T care with 24/7 monitoring A multidisciplinary team (hematology, oncology, immunology) A supportive, patient- and family-centered environment Full international patient services, including travel and care coordination Proven Outcomes and Global Leadership Sheba is a global leader in CAR-T therapy, with strong clinical outcomes: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The program is experienced in treating complex and high-risk leukemia cases, offering options when other treatments are limited. Comprehensive Evaluation and Ongoing Support Each patient undergoes a full diagnostic work-up, including: advanced imaging, bone marrow biopsy, genetic and molecular testing, as well as cardiac and pulmonary evaluation. Care is provided in English, Russian, and Arabic, ensuring clear communication and continuous support for international families. A Place Patients and Families Can Trust By combining advanced science, rapid access to treatment, and compassionate care, Sheba offers one of the most trusted CAR-T programs for leukemia focused on achieving remission and helping patients return to a healthy, active life.","is_package":true},{"id":"69e975cfb046df7de7039a02","clinic_id":9,"clinic_listed":true,"price":84200,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Biochemistry blood test","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric CAR-T Program for Non-Hodgkin Lymphomas (DLBCL, FL, MCL) At Sheba Medical Center, children and young patients with Non-Hodgkin lymphomas have access to one of the most advanced and trusted CAR-T therapy programs in the world. The program focuses on treating diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL), especially in relapsed or treatment-resistant cases using highly personalized immunotherapy. A Personalized Treatment Designed for Each Child CAR-T therapy uses the patient’s own immune system to identify and destroy cancer cells. This approach offers new hope for children and young patients when standard therapies are no longer effective. At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center Infusion – reintroduction of modified cells to target lymphoma Because no steps are outsourced, treatment can begin quickly and is typically completed within ~10 days. CAR-T functions as a “living therapy,” continuing to work in the body over time and offering the potential for long-term remission. Expert Pediatric Leadership and Care The pediatric CAR-T program is led by Prof. Amos Toren, one of the most experienced specialists in pediatric hemato-oncology and cellular therapies, with decades of experience and over 1,500 bone marrow transplants performed. The program includes: Dedicated pediatric CAR-T units with 24/7 expert monitoring A multidisciplinary team of hemato-oncologists, immunologists, and pediatric specialists A supportive, family-centered environment designed for children Full international patient support, including travel and care coordination Proven Outcomes and Global Expertise Sheba is a global leader in pediatric CAR-T therapy, with strong clinical outcomes: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults The program is highly experienced in treating complex and high-risk lymphoma cases, offering advanced options when other treatments have been exhausted. Comprehensive Evaluation and Support Each child undergoes a thorough diagnostic evaluation, including: advanced imaging, bone marrow testing, genetic and molecular profiling, and full cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, ensuring families feel supported and informed at every stage. A Trusted Place for Advanced Pediatric Cancer Care By combining cutting-edge science, rapid access to treatment, and compassionate pediatric care, Sheba provides one of the most trusted environments for treating Non-Hodgkin lymphomas with CAR-T therapy focused on achieving remission and helping children return to a healthy, active life.","is_package":true},{"id":"69e932dc18284bfa1d0a0d02","clinic_id":9,"clinic_listed":true,"price":86000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Blood tests","Chest X-ray","Anti-HIV test","Anti-HBC test","Anti-HCVAb test","Echocardiography","Complete blood count (CBC)","Biochemistry blood test","Consultation with an oncologist","Consultation with a hematologist","Consultation with a pediatric hematologist","Consultation with a pediatrician","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","Hospitalization","Transfer airport-hotel-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"Sheba Pediatric Personalized CAR-T Immunotherapy Program for Blood Cancers At Sheba Medical Center, children and young patients receive some of the most advanced and compassionate cancer care available today. Sheba is a global leader in pediatric CAR-T cell therapy, offering highly personalized treatment for complex and resistant blood cancers, including: • Acute lymphoblastic leukemia (ALL) and Acute Myeloid Leukemia (AML) • Non-Hodgkin lymphomas (DLBCL, FL, MCL) • Burkitt lymphoma • CLL / Richter’s transformation • Primary CNS lymphoma • Multiple myeloma A Gentle, Fully Integrated CAR-T Journey Every step of the CAR-T process is performed on-site at Sheba, ensuring speed, safety, and the highest quality of care, especially important for children. The treatment includes three carefully coordinated stages: • Apheresis – collecting the child’s own immune (T) cells • Cell Engineering – reprogramming the cells at Sheba’s Advanced Biotherapy Center • Infusion – returning the cells to fight the cancer Because everything is done within the hospital, treatment can begin quickly and is typically completed within ~10 days. CAR-T works as a “living therapy,” continuing to act in the body and offering the potential for long-term remission. All patients are treated under the guidance of leading experts, including Prof. Amos Toren, with dedicated pediatric CAR-T teams ensuring continuous monitoring and care. Designed Especially for Children and Families Sheba understands that treating a child means caring for the entire family. The pediatric program offers: • Specialized pediatric CAR-T units with 24/7 expert monitoring • A multidisciplinary team of hemato-oncologists, immunologists, and pediatric specialists • A supportive, child-friendly environment focused on comfort and safety • Full international patient support, including travel and care coordination Clinical Excellence You Can Trust Sheba is one of the world’s leading centers in pediatric CAR-T, with strong clinical outcomes: • ~90% remission in pediatric patients • ~80% in young adults (up to 23 years) • ~70% in adults Importantly, Sheba offers flexibility in age criteria, ensuring that children and young patients can access advanced therapies when needed. Comprehensive Care from Start to Finish Each child receives a complete evaluation before treatment, including: advanced imaging, bone marrow testing, genetic and molecular analysis, and full cardiac and pulmonary assessment. Care is provided in English, Russian, and Arabic, helping families feel supported and informed throughout the entire journey. Why Families Choose Sheba By combining advanced science, speed, and deeply personalized care, Sheba provides one of the most trusted pediatric CAR-T programs in the world focused not only on treating disease, but on giving children the best possible chance to return to a healthy, active life.","is_package":true},{"id":"69d6029bedb8b85c1a0bd0e2","clinic_id":9,"clinic_listed":true,"price":86000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Blood tests","Follow-up examination","Ultrasound","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Multiple Myeloma at Sheba Medical Center For patients diagnosed with Multiple Myeloma, especially those with relapsed or treatment-resistant disease, access to advanced therapies can significantly change outcomes. Sheba Medical Center, one of the world’s leading hospitals, offers state-of-the-art CAR-T cell therapy, providing new hope when standard treatments are no longer effective. Sheba combines innovative immunotherapy, extensive clinical experience, and rapid access to treatment to deliver highly personalized care for complex myeloma cases. A Faster Path to Advanced Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality what is a key advantage for patients requiring timely intervention. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to recognize and destroy myeloma cells By avoiding external laboratories, treatment can begin in approximately 10 days, significantly reducing waiting time compared to many international centers. CAR-T therapy acts as a “living therapy,” continuing to function within the body and offering the potential for deep and durable remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. A Powerful Option for Advanced Myeloma Multiple Myeloma often requires multiple lines of therapy over time. At Sheba, hematologists, oncologists, and immunotherapy specialists work together to develop a personalized treatment strategy, especially for patients who have exhausted conventional options. CAR-T therapy has shown promising and durable responses in advanced myeloma, offering a new therapeutic pathway where alternatives may be limited. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – one of the leading CAR-T programs in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary expertise – integrated care across specialties • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a complete diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and full medical assessment, ensuring a precise, individualized treatment plan. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. A Leading Center for Advanced Myeloma Treatment By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for Multiple Myeloma worldwide offering patients a real opportunity for long-term disease control and improved quality of life.","is_package":true},{"id":"69d5fbe0fe4c90900e071d75","clinic_id":9,"clinic_listed":true,"price":86000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Blood tests","Follow-up examination","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a pediatric hematologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"CAR-T Therapy for Burkitt Lymphoma at Sheba Medical Center For patients diagnosed with Burkitt Lymphoma, one of the most aggressive and fast-growing types of lymphoma, timing and access to advanced treatment are critical. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease. Sheba combines rapid treatment access, cutting-edge immunotherapy, and extensive clinical expertise to manage even the most challenging and fast-progressing cases. A Faster Path to Life-Saving Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality essential for aggressive diseases like Burkitt Lymphoma. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to rapidly target and destroy lymphoma cells By eliminating the need for external laboratories, treatment can begin in approximately 10 days, significantly reducing delays compared to many international centers. CAR-T therapy acts as a “living therapy,” continuing to work in the body and offering the potential for rapid and durable remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Advanced Treatment for Aggressive Disease Burkitt Lymphoma requires immediate and highly specialized care. At Sheba, hematologists, oncologists, and immunotherapy experts work together to design a personalized treatment strategy, tailored to the urgency and biology of each case. CAR-T therapy offers a powerful option for patients who have exhausted standard treatments, providing meaningful responses even in highly aggressive disease settings. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – leading CAR-T program in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary expertise – integrated care across specialties • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise and individualized treatment plan. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. A Leading Center for Advanced Lymphoma Care By combining speed, innovation, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for Burkitt Lymphoma worldwide offering patients a real chance for remission and improved survival in one of the most aggressive cancers.","is_package":true},{"id":"69d5ae553eb001ab1907ddb2","clinic_id":9,"clinic_listed":true,"price":85000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Ultrasonography (USG)","Electrocardiogram (ECG)","Consultation with a doctor","Blood tests","Follow-up examination","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for CLL / Richter’s Transformation at Sheba Medical Center For patients diagnosed with Chronic Lymphocytic Leukemia (CLL) or Richter’s Transformation, a more aggressive progression of the disease, finding an effective treatment option can be especially challenging. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease. Sheba combines cutting-edge immunotherapy with deep expertise in complex hematologic cancers, delivering personalized solutions even in the most aggressive cases. A Faster Path to Advanced Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, a critical advantage for patients with rapidly progressing disease. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to identify and destroy cancer cells By eliminating the need for external laboratories, treatment can begin in approximately 10 days, significantly reducing delays compared to many international centers. CAR-T therapy acts as a “living therapy,” continuing to work in the body and offering the potential for deep and durable remission, even in aggressive disease forms like Richter’s transformation. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Advanced Treatment for Complex Cases CLL and Richter’s transformation often require highly specialized care. At Sheba, hematologists, oncologists, and immunotherapy experts work together to design the most effective, individualized treatment strategy. CAR-T therapy provides a promising option for patients who have exhausted conventional therapies, offering meaningful clinical responses and improved outcomes in difficult-to-treat cases. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – one of the leading CAR-T programs in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary expertise – integrated care across specialties • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a complete diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and full medical assessment, ensuring a precise, personalized treatment plan. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. A Leading Center for Advanced Hemato-Oncology Care By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for CLL and Richter’s transformation worldwide offering patients a real opportunity for disease control and improved quality of life.","is_package":true},{"id":"69d5ab7cc88c3f9bfe0451b2","clinic_id":9,"clinic_listed":true,"price":85300,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Post-operative care","3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Preoperative tests","Blood tests","Follow-up examination","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with an immunologist","Consultation with a pediatric hematologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Acute Lymphoblastic Leukemia (ALL) at Sheba Medical Center For patients diagnosed with Acute Lymphoblastic Leukemia (ALL), especially those with relapsed or treatment-resistant disease, access to advanced therapy can be life-changing. Sheba Medical Center, ranked among the World's Top 10 Hospitals by Newsweek 2026, offers state-of-the-art CAR-T cell therapy, providing new hope where conventional treatments may no longer be effective. Sheba Medical Center is internationally recognized for its expertise in advanced cellular therapies, including CAR-T therapy for ALL, particularly in pediatric and young adult patients, combining cutting-edge science with extensive clinical experience. A Faster Path to Life-Saving Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality, critical in fast-progressing diseases like ALL. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reinfusion of modified cells designed to target and eliminate leukemia cells By keeping the entire process in-house, treatment can begin in approximately 10 days, significantly faster than many international centers. CAR-T therapy acts as a “living drug,” continuing to work in the body and offering the potential for deep and lasting remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Outstanding Outcomes That Offer Real Hope These outcomes provide a powerful treatment option and a second chance for patients with limited alternatives. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – leading CAR-T program in the region • Dedicated CAR-T units – specialized care with 24/7 monitoring • Multidisciplinary expertise – hematology, oncology, and immunotherapy teams working together • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a full diagnostic evaluation, including advanced imaging, bone marrow biopsy, genetic and molecular testing, and complete medical assessment, ensuring a precise, individualized treatment plan. Services are available in English, Russian, and Arabic, providing a seamless experience for international patients and their families. By combining innovative CAR-T technology, in-house cell production, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for ALL worldwide, offering patients not just treatment, but a real opportunity for remission and renewed life.","is_package":true},{"id":"69d5a663ac1ed88d6d0521f2","clinic_id":9,"clinic_listed":true,"price":86300,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Post-operative care","3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Preoperative tests","Blood tests","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Consultation with a surgeon","Consultation with a neurologist","Consultation of a radiologist","Сonsultation with an oncohematologist","Head MRI","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Primary CNS Lymphoma at Sheba Medical Center For patients diagnosed with Primary central nervous system Lymphoma (PCNSL), a rare and complex cancer affecting the brain and central nervous system, choosing the right treatment center is critical. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope for patients with relapsed or treatment-resistant disease. Sheba combines cutting-edge immunotherapy with deep expertise in neuro-oncology, delivering highly personalized care for even the most challenging cases. A Faster Path to Advanced Treatment At Sheba, the entire CAR-T process is performed on-site, ensuring speed, precision, and optimal cell quality crucial for patients with aggressive CNS disease. • Apheresis – collection of the patient’s T-cells • Cell Engineering – genetic modification at Sheba’s Advanced Biotherapy Center • Infusion – reintroduction of modified cells designed to target lymphoma cells, including those within the central nervous system By avoiding external laboratories, treatment can begin in approximately 10 days, significantly reducing delays and allowing faster access to life-saving therapy. CAR-T acts as a “living therapy,” continuing to work inside the body and offering the potential for long-term disease control and remission. All patients are treated under the leadership of Prof. Arnon Nagler, a globally recognized expert in hemato-oncology. Proven Expertise in Complex Cases Primary CNS lymphoma requires a highly specialized, multidisciplinary approach. At Sheba, hematologists, neuro-oncologists, neurologists, and imaging specialists work together to design the most effective treatment strategy for each patient. CAR-T therapy offers a promising option for patients who have exhausted conventional treatments, with encouraging remission outcomes even in advanced cases. Why Patients Choose Sheba • Rapid access to CAR-T therapy – treatment initiation in ~10 days • Extensive experience – leading CAR-T program in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary CNS expertise – integrated hematology and neuro-oncology care • Full international support – medical review, travel coordination, and patient assistance Comprehensive, Personalized Care Each patient undergoes a full evaluation, including advanced brain imaging (MRI/CT), molecular and genetic testing, and complete medical assessment, ensuring a precise and individualized treatment plan. Services are available in English, Russian, and Arabic, providing a smooth and supportive experience for international patients. A Leading Center for Advanced Neuro-Oncology Care By combining innovative CAR-T technology, in-house cell production, and multidisciplinary expertise, Sheba offers one of the most advanced treatment options for Primary CNS Lymphoma worldwide giving patients access to therapies that can extend survival and improve quality of life.","is_package":true},{"id":"69cedd2f69a067457406e684","clinic_id":9,"clinic_listed":true,"price":86000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["3 meals per day by nutritionist","24-hr nurse services","CT Scan","Electrocardiogram (ECG)","Consultation with a doctor","Blood tests","Follow-up examination","Ultrasound","Echocardiography","Biochemistry blood test","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Follow-up visit","Consultation with an immunologist","Consultation with a neurologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Сonsultation with an oncohematologist","Complete blood count with cancer markers and a proteinogram","CT angiography","Hospitalization","Transfer airport-clinic-airport"],"excluded":{"status":"missing","reason":"not_collected"},"other_services":"CAR-T Therapy for Non-Hodgkin Lymphomas (DLBCL, FL, MCL) at Sheba Medical Center For patients facing relapsed or resistant Non-Hodgkin lymphoma, finding the right treatment center can make a life-changing difference. Sheba Medical Center, one of the world’s leading hospitals, offers advanced CAR-T cell therapy, providing new hope when standard treatments are no longer effective. Sheba specializes in treating DLBCL, Follicular Lymphoma (FL), and Mantle Cell Lymphoma (MCL) with a highly personalized approach, combining cutting-edge science, speed, and clinical expertise. A Faster Path to Treatment When Time Matters Most At Sheba, the entire CAR-T process is performed on-site, without delays caused by external laboratories. • T-cells are collected (apheresis) • Genetically engineered at Sheba’s Advanced Biotherapy Center • Reinfused to target and destroy lymphoma cells This streamlined approach allows treatment to begin in approximately 10 days, significantly faster than many international centers. CAR-T therapy acts as a “living drug”, continuing to work inside the body and offering the potential for long-term remission. All patients are treated under the leadership of Prof. Arnon Nagler, a world-renowned expert in hemato-oncology. Proven Results That Offer Real Hope Even in complex and advanced cases, CAR-T therapy at Sheba has demonstrated high remission rates • Up to 90% in pediatric patients These outcomes provide a meaningful second chance for patients who have exhausted other options. Why Patients Choose Sheba • Rapid access to treatment – no waiting weeks for cell production • Extensive experience – one of the largest CAR-T programs in the region • Dedicated CAR-T units – with 24/7 expert monitoring • Multidisciplinary care – leading specialists working together on every case • Full international support – from medical review to travel and coordination Comprehensive, Personalized Care Each patient undergoes a complete evaluation, including advanced imaging, genetic and molecular testing, and full medical assessment, ensuring the most effective, tailored treatment plan. Services are available in English, Russian, and Arabic, making the experience smooth and supportive for international patients. A Global Leader in Advanced Cancer Care By combining speed, innovation, and world-class expertise, Sheba delivers one of the most advanced and accessible CAR-T programs for lymphoma patients worldwide, offering not just treatment, but a real opportunity for remission and renewed quality of life.","is_package":true},{"id":"69ced4fb69a067457406e683","clinic_id":9,"clinic_listed":true,"price":85000,"nights":21,"transfer":{"status":"missing","reason":"not_collected"},"tests":{"status":"missing","reason":"not_collected"},"meds":{"status":"missing","reason":"not_collected"},"aftercare":{"status":"missing","reason":"not_collected"},"guarantee":{"status":"missing","reason":"not_collected"},"included":["Ultrasound biomicroscopy (UBM)","3 meals per day by nutritionist","24-hr nurse services","CT Scan","Ultrasonography (USG)","Blood tests","Follow-up examination","Ultrasound","Ultrasonography","Complete blood count (CBC)","PET/CT","Consultation with an oncologist","Consultation with a hematologist","Follow-up visit","Consultation with an immunologist","Consultation with a neurologist","Consultation with a cardiologist","Consultation with a pediatric hematologist","Consultation of a radiologist","Сonsultation with an oncohematologist","Biopsy","Complete blood count with cancer markers and a proteinogram","CT angiography","Transfer airport-clinic-airport"],"excluded":["Accommodation is not included"],"other_services":"CAR-T Therapy at Sheba Medical Center Sheba Medical Center is high expertised in CAR-T cell therapy, offering advanced, personalized treatment for a wide range of hematologic cancers, including: Non-Hodgkin lymphomas (DLBCL, FL, MCL), primary CNS lymphoma, ALL, CLL/Richter’s transformation, Burkitt lymphoma, and multiple myeloma. A Fast, Fully Integrated CAR-T Process At Sheba, the entire CAR-T procedure is performed on-site, ensuring speed, precision, and optimal cell quality. The process includes three key steps: Apheresis – collection of the patient’s T-cells Cell Engineering – genetic modification at the Advanced Biotherapy Center Infusion – reintroduction of modified cells to target cancer Unlike many centers, Sheba does not send cells abroad. This allows treatment to be completed in approximately 10 days, making CAR-T a true “living drug” capable of long-term remission. All patients are evaluated and treated under the supervision of Prof. Arnon Nagler, a leading expert in hemato-oncology. Why Choose Sheba for CAR-T Rapid access – on-site production reduces waiting time from weeks to ~10 days Extensive experience – largest CAR-T program in Israel and the region Dedicated CAR-T units – for both adults and children, with 24/7 monitoring Multidisciplinary care – hematology, oncology, immunology experts working together Global patient services – full support with medical coordination and travel logistics Clinical Excellence & Outcomes Sheba is a global leader in pediatric CAR-T, with no strict age limitations for pediatric patients. Reported outcomes show: ~90% remission in pediatric patients ~80% in young adults (up to 23 years) ~70% in adults Comprehensive Evaluation & Support Each patient undergoes a thorough diagnostic work-up, including: physician consultations, advanced imaging (CT, ultrasound, nuclear medicine), bone marrow biopsy, genetic and molecular testing (FISH, karyotyping), cardiac and pulmonary evaluation, and laboratory testing. Services are provided in English, Russian, and Arabic, ensuring a smooth and supportive experience for international patients. Key Advantage By combining in-house cell manufacturing, leading expertise, and integrated care, Sheba delivers one of the fastest, most advanced, and most personalized CAR-T programs.","is_package":true}],"related_packages":{"status":"missing","reason":"not_collected"},"other_packages":{"status":"missing","reason":"not_classified"}},"medical":{"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"hospital_nights":{"value":21,"source":"offers","parsed_details":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."}},"treatment_conditions":["inpatient"],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"horizon":"Best response, typically assessed at 1-3 months after infusion","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Complete blood count","aliases":["Complete blood count","CBC","Full blood count"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"},{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Biopsy","aliases":["Biopsy","Bone marrow biopsy"],"kind":"other","origin":[{"field":"initial_assessment_documents","text":"Bone marrow biopsy report"},{"field":"packages","text":"Biopsy"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"PET-CT scan","aliases":["PET-CT scan","PET-CT","PET/CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"PET/CT"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"MRI scan","aliases":["MRI scan","MRI","Head MRI"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"Head MRI"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Echocardiogram","aliases":["Echocardiogram","Echocardiography"],"kind":"heart","origin":[{"field":"initial_assessment_documents","text":"Echocardiogram report (if available)"},{"field":"packages","text":"Echocardiography"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Kidney function test","aliases":["Kidney function test","Kidney function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Liver function test","aliases":["Liver function test","Liver function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"Tumor marker test","aliases":["Tumor marker test","Cancer markers"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T10","name":"Serum protein electrophoresis","aliases":["Serum protein electrophoresis","Proteinogram"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"prep_in_advance":{"status":"ok","items":[{"id":"P1","action":"Ask your team whether chemotherapy or radiation will be given before the T cells are returned to you","why":"The treatment aims to get rid of other immune cells","who_decides":"prescriber","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"During this time, you may have treatment with chemotherapy and, maybe, radiation therapy to get rid of other immune cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"visit_and_day":{"status":"ok","has_procedure_day":true,"items":[{"id":"V1","text":"The CAR T-cell product is sent back to the hospital and returned to the patient as a single infusion","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"These expanded cells are the final CAR T-cell therapy product, which is sent back to the hospital to be returned to the patient as a single infusion.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},{"id":"V2","text":"The T cells grown in the lab are given back to the patient through a needle in a vein","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"After these treatments, the T cells that were grown in the lab will be given back to you via a needle in your vein.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":60,"max":90,"unit":"days","qualifier":"Desk work usually resumes at 2–3 months, once CRS/ICANS risk and cytopenias settle. Later if fatigue, neurotoxicity or infections persist."},"complication_rate_pct":{"min":50,"max":95,"unit":"percent","qualifier":"Any-grade cytokine release syndrome or neurotoxicity within about 8 weeks; severe grade 3+ events roughly 10-25%."},"contraindications":["Active uncontrolled infection, including uncontrolled hepatitis B/C or HIV","Significant cardiac, pulmonary, renal or hepatic dysfunction","Active CNS or autoimmune neurological disease (relative, product-dependent)","Poor performance status or rapid progression during manufacturing (relative)","Severe hypersensitivity to DMSO or product excipients","Pregnancy or breastfeeding","Active uncontrolled graft-versus-host disease (relative, prior transplant)"],"days_in_clinic":{"min":10,"max":21,"unit":"nights","qualifier":"Inpatient stay with daily CRS/ICANS monitoring, about 2 weeks; longer if ICU needed."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":8,"max":12,"unit":"weeks","qualifier":"Strenuous exercise waits about 2–3 months, until counts recover and early neurotoxicity and infection risk passes. Light walking earlier."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Response is assessed at about 1 month and 3 months after infusion; remission durability needs longer follow-up."},"fly_home_after_days":{"min":28,"max":42,"unit":"days","qualifier":"Stay near the centre at least 4 weeks, past peak CRS/ICANS risk. Fly if no toxicity, counts acceptable."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":7,"max":14,"unit":"days","qualifier":"Frequent early monitoring for cytokine release syndrome and neurotoxicity if discharged"}},{"purpose":"result_review","requirement":"routine","after":{"min":28,"max":35,"unit":"days","qualifier":"First response assessment, about day 28-35 after infusion"}},{"purpose":"result_review","requirement":"routine","after":{"min":85,"max":100,"unit":"days","qualifier":"Response reassessment about day 85-100 (around 3 months) after infusion"}}],"indications":["Relapsed or refractory large B-cell lymphoma","Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory follicular and mantle cell lymphoma","Relapsed or refractory multiple myeloma (BCMA-directed)","Relapsed or refractory chronic lymphocytic leukemia"],"main_risks":["Cytokine release syndrome","Immune effector cell-associated neurotoxicity syndrome","Prolonged cytopenias","Infections and hypogammaglobulinemia","B-cell aplasia","Hemophagocytic lymphohistiocytic-like syndrome","Secondary T-cell malignancies (rare)","Tumor lysis syndrome","Infusion-related hypersensitivity reactions"],"pain":"The infusion itself is generally painless; fever, headache, body aches and malaise may occur with cytokine release, and leukapheresis involves line placement with mild discomfort.","preparation":["Specialist eligibility assessment and disease staging","Infection screening and organ function evaluation","Leukapheresis to collect the patient's T cells","Possible bridging therapy while the cells are manufactured (weeks)","Lymphodepleting chemotherapy a few days before infusion","Central venous access as needed","Arrange nearby accommodation and a caregiver after infusion","Confirm target antigen (e.g., CD19, BCMA) and prior-therapy eligibility","Pre-infusion premedication (paracetamol and antihistamine)","Access to tocilizumab and ICU-level support before infusion"],"recovery_timeline":[{"phase":"Infusion and first 1-2 weeks","description":"Single IV infusion followed by close monitoring for cytokine release syndrome and neurotoxicity, usually peaking in the first 1-2 weeks.","restrictions":["Stay near the treatment center"]},{"phase":"Weeks 2-4","description":"Discharge when stable, frequent visits, blood count and infection monitoring, first response assessment around day 28.","restrictions":["Stay near the treatment center until about day 28","No driving for at least 8 weeks","Avoid crowds and infection exposure"]},{"phase":"Months 2-12","description":"Gradual recovery of blood counts and energy, immune function monitoring, immunoglobulin replacement if needed, response reassessment.","restrictions":["Delay live vaccines per specialist advice"]}],"rehabilitation_days":{"min":60,"max":90,"unit":"days","qualifier":"Functional recovery after the 4-week monitoring period; slower with persistent fatigue, cytopenias, neurotoxicity or infections."},"result_longevity":"In large B-cell lymphoma, about 40% remain progression-free at 1 year; some stay in long-term remission. In B-ALL, about 36% relapse; CAR T cells can persist up to about 5 years.","revision_rate_pct":null,"scars":"There is no surgical incision, only small puncture marks from the leukapheresis or central venous line sites.","sessions_or_stages":{"sessions":{"min":1,"max":1,"unit":"visits","qualifier":"One CAR T-cell infusion; leukapheresis and lymphodepletion are preceding stages."},"stages":[{"code":"leukapheresis","label":"Leukapheresis to collect T cells","after":{"min":0,"max":0,"unit":"days","qualifier":"Starting point of the treatment pathway"}},{"code":"lymphodepletion","label":"Lymphodepleting chemotherapy","after":{"min":23,"max":58,"unit":"days","qualifier":"About 3-8 weeks after leukapheresis; 2-5 days before infusion"}},{"code":"car_t_infusion","label":"CAR T-cell infusion","after":{"min":28,"max":63,"unit":"days","qualifier":"Depends on manufacturing and product release time"}}],"qualifier":"Single-infusion therapy; timelines vary by product and center."},"success":{"metric":"Complete response rate in relapsed/refractory large B-cell lymphoma (3rd-line or later)","value":51,"unit":"percent","horizon":"Best response, typically assessed at 1-3 months after infusion","evidence_status":"limited","population":"Adults with relapsed/refractory LBCL after two or more prior lines"},"techniques":[{"name":"Autologous CD19-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"name":"Autologous BCMA-directed CAR T-cell therapy","suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","recovery":"Similar monitoring; prolonged cytopenias are common."}],"treatment_conditions":["inpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Duration of the single CAR T-cell infusion itself; leukapheresis (about 3-6 hours) and lymphodepletion are separate."},"initial_assessment_documents":["Pathology report with CD19 or BCMA status","Summary of prior treatment lines and responses","Recent PET-CT or MRI report","Bone marrow biopsy report","Recent CBC, kidney and liver function tests","Echocardiogram report (if available)"],"travel_trips":{"min":1,"max":2,"one_trip_possible":true,"qualifier":"Cell collection, then 3-9 weeks manufacturing, usually at home; return for infusion and 4+ weeks nearby. One trip means staying."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Ask the clinic for examples of the practitioners' experience with the exact procedure you are planning","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Ask for examples of the practitioners’ experience with the surgery you are intending to have.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Ask whether a doctor is always present in the clinic and whether a high dependency or intensive care unit exists","scope":"treatment_abroad","source":{"url":"https://www.bapras.org.uk/public/patient-information/cosmetic-surgery/cosmetic-surgery-abroad","host":"bapras.org.uk","quote":"Is there always a doctor in the clinic and is there a high dependency or intensive care unit?","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C3","text":"Confirm the surgeon is trained and experienced in the exact procedure you are considering, not just in surgery generally","scope":"treatment_abroad","source":{"url":"https://www.isaps.org/discover/patients-home/considering-your-procedure-abroad/finding-a-surgeon-abroad/","host":"isaps.org","quote":"Verify that the surgeon is trained and experienced in performing the procedure you are considering.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C4","text":"Check that the surgeon who consults with you is the same person who will carry out the procedure","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Check that the surgeon you consult with, will be the same person carrying out the procedure.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"C5","text":"Decide before you travel where check-ups after the operation will take place, because follow-up abroad may be missing or weaker","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/conditions/cosmetic-procedures/cosmetic-surgery-abroad/","host":"nhs.uk","quote":"You need to think about where check-ups will take place.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Pressure to decide quickly, or cheap time-limited offers, is a warning sign of a clinic offer","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Confusion or difficulty communicating","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Patients also may experience neurologic symptoms such as confusion, tremors, or difficulty communicating.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Excessive sleepiness","urgency":"contact_clinic","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"Some of the hallmark signs of ICANS include confusion, excessive sleepiness, and impaired speech.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Trouble breathing","urgency":"emergency","general":false,"source":{"url":"https://www.cancer.gov/about-cancer/treatment/side-effects/flu-symptoms","host":"cancer.gov","quote":"Immunotherapy treatments such as CAR T-cell therapy and some monoclonal antibodies may cause cytokine release syndrome (CRS), a condition that can lead to severe flu-like symptoms as well as a rash, rapid heartbeat, low blood pressure, and trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Fever","urgency":"contact_clinic","general":true,"source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2019/cancer-immunotherapy-investigating-side-effects","host":"cancer.gov","quote":"Many patients who receive CAR T-cell therapy develop a condition known as cytokine release syndrome, which can cause a fever, fast heart rate, low blood pressure, and rash, among other symptoms.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Shows emergency staff and other doctors the patient is a CAR T recipient","document":"car t wallet card","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Carry your wallet card with you at all times.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Home doctor needs the plan the treating team set for leaving hospital","document":"written discharge instructions","source":{"url":"https://www.mskcc.org/cancer-care/patient-education/car-cell-therapy-guide-adult-patients-caregivers","host":"mskcc.org","quote":"Your CAR T team will give you discharge instructions before you leave the hospital.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T3","text":"Home doctor needs the exact medicines to continue treatment safely","document":"discharge medicines list","source":{"url":"https://www.cuh.nhs.uk/patient-information/discharge-advice-from-ward-c10c9-following-car-t-cell-therapy/","host":"cuh.nhs.uk","quote":"You will be given a copy of all the medications that you should take after being discharged.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Complete blood count","aliases":["Complete blood count","CBC","Full blood count"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"},{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Biopsy","aliases":["Biopsy","Bone marrow biopsy"],"kind":"other","origin":[{"field":"initial_assessment_documents","text":"Bone marrow biopsy report"},{"field":"packages","text":"Biopsy"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"PET-CT scan","aliases":["PET-CT scan","PET-CT","PET/CT"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"PET/CT"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"MRI scan","aliases":["MRI scan","MRI","Head MRI"],"kind":"imaging","origin":[{"field":"initial_assessment_documents","text":"Recent PET-CT or MRI report"},{"field":"packages","text":"Head MRI"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Echocardiogram","aliases":["Echocardiogram","Echocardiography"],"kind":"heart","origin":[{"field":"initial_assessment_documents","text":"Echocardiogram report (if available)"},{"field":"packages","text":"Echocardiography"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Kidney function test","aliases":["Kidney function test","Kidney function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Liver function test","aliases":["Liver function test","Liver function tests"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"Recent CBC, kidney and liver function tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"Blood tests","aliases":["Blood tests"],"kind":"lab","origin":[{"field":"packages","text":"Blood tests"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"Tumor marker test","aliases":["Tumor marker test","Cancer markers"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T10","name":"Serum protein electrophoresis","aliases":["Serum protein electrophoresis","Proteinogram"],"kind":"lab","origin":[{"field":"packages","text":"Complete blood count with cancer markers and a proteinogram"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"prep_in_advance":{"status":"ok","items":[{"id":"P1","action":"Ask your team whether chemotherapy or radiation will be given before the T cells are returned to you","why":"The treatment aims to get rid of other immune cells","who_decides":"prescriber","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"During this time, you may have treatment with chemotherapy and, maybe, radiation therapy to get rid of other immune cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"visit_and_day":{"status":"ok","has_procedure_day":true,"items":[{"id":"V1","text":"The CAR T-cell product is sent back to the hospital and returned to the patient as a single infusion","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/research/car-t-cells","host":"cancer.gov","quote":"These expanded cells are the final CAR T-cell therapy product, which is sent back to the hospital to be returned to the patient as a single infusion.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},{"id":"V2","text":"The T cells grown in the lab are given back to the patient through a needle in a vein","anesthesia":"any","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy","host":"cancer.gov","quote":"After these treatments, the T cells that were grown in the lab will be given back to you via a needle in your vein.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":1},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}}},"techniques":[{"id":"autologous-cd19-directed-car","name":"Autologous CD19-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Modified T cells recognize an antigen on cancer cells","source":{"url":"https://www.leedsth.nhs.uk/?p=50458","host":"leedsth.nhs.uk","quote":"These new receptors will enable the T-cells to recognise and attach to the antigen on the cancer cell.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory B-cell lymphomas and B-ALL","price_from":150000,"recovery":"Inpatient monitoring about 10-21 days, then nearby follow-up to day 28."},{"id":"autologous-bcma-directed-car","name":"Autologous BCMA-directed CAR T-cell therapy","how_it_works":{"id":"H1","text":"Engineered cells are designed to recognize BCMA, a protein on myeloma cells","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-ide-cel-car-t-multiple-myeloma","host":"cancer.gov","quote":"genetic engineering lets the CAR T cells \"see\" BCMA, a protein that's present at high amounts in multiple myeloma cells","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Relapsed/refractory multiple myeloma after multiple prior lines","price_from":86000,"recovery":"Similar monitoring; prolonged cytopenias are common."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"You are older and not eligible for CAR T-cell therapy","name":"Bispecific antibody therapy","source":{"url":"https://www.cancer.gov/news-events/cancer-currents-blog/2022/tecvayli-multiple-myeloma","host":"cancer.gov","quote":"with bispecific antibodies you'll be able to treat older patients who are not eligible for CAR T-cell therapies","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"British citizens can visit Israel as tourists without a visa","source":{"url":"https://www.gov.uk/foreign-travel-advice/israel/entry-requirements","host":"gov.uk","quote":"You can visit Israel without a visa as a tourist.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"passport_validity","audience":"uk","volatile":true,"text":"To enter Israel, your passport must have an expiry date at least 90 days after the date you arrive","source":{"url":"https://www.gov.uk/foreign-travel-advice/israel/entry-requirements","host":"gov.uk","quote":"To enter Israel or Palestine, your passport must have an ‘expiry date’ at least 90 days after the date you arrive.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V3","item":"arrival_form","audience":"uk","volatile":true,"text":"Visitors must get an Electronic Travel Authorisation (ETA) before arriving in Israel","source":{"url":"https://www.gov.uk/foreign-travel-advice/israel/entry-requirements","host":"gov.uk","quote":"As of 1 January 2025, to visit Israel you will need to get an Electronic Travel Authorisation (ETA) before you arrive.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"hospital_payment","audience":"all","volatile":false,"text":"Hospitals in Israel insist on payment and may take legal action to stop you leaving until bills are paid","source":{"url":"https://www.gov.uk/foreign-travel-advice/israel/health","host":"gov.uk","quote":"Hospitals will insist on payment and may take legal action to stop you leaving until bills are paid.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["austria","china","germany","italy","lithuania","republic-of-korea","spain","thailand","turkey","united-kingdom","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.48,"count":187,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>CAR T-cell therapy in Israel ranges from _op_800_price_from_ to _op_800_price_to_ depending on the protocol type. Costs vary based on whether hospitals use in-house \"home-grown\" cells or commercial FDA-approved products. Patients save approximately _price_percent_discount_% compared to the US, where the average price is _price_compare_US_average_. Israeli packages typically include cell collection, genetic engineering, chemotherapy, and a 21-day hospital stay with monitoring.</p>\n\n<ul>\n<li><strong>In-house protocols:</strong> Typically cost $80,000 to $150,000 for locally manufactured cell treatments.</li>\n<li><strong>Commercial products:</strong> Prices for FDA-approved drugs like Kymriah range from $366,000 to $475,000.</li>\n<li><strong>Hospitalization:</strong> Most quotes include 21 to 28 days of inpatient care for safety monitoring.</li>\n<li><strong>Destination hubs:</strong> Primary treatment centers are located in Tel Aviv, Jerusalem, and Ramat Gan.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight:</strong> Choosing in-house protocols at centers like Sheba Medical Center can reduce costs by 60%. These \"home-grown\" treatments avoid high US shipping fees and shorten processing to 10 days. For commercial cases, Sourasky Medical Center offers packages around $367,000. These include 21 days of hospitalization and 14 days of hotel stay. Expert directors like Dr. Ron Ram provide high-volume experience in these complex cell transplants.</p>","faq":[{"q":"What is the effectiveness and success rate of CAR T-cell therapy in Israel?","a":"<p>CAR T-cell therapy in Israel delivers remarkable success rates between 70% and 90% for specific blood cancers like multiple myeloma and pediatric leukemia. These outcomes match global standards within JCI-accredited facilities. Specialized centers currently provide faster, in-house cell production, reducing critical treatment delays for high-risk lymphoma and leukemia patients.</p> <ul> <li><strong>Remission rates:</strong> Patients with pediatric acute lymphoblastic leukemia achieve 90% remission at top-rated centers.</li> <li><strong>Treatment speed:</strong> In-house manufacturing at Sheba Medical Center cuts production time to 10–11 days.</li> <li><strong>Long-term durability:</strong> Many patients maintain progression-free survival for 2–5 years following personalized immunotherapy.</li> <li><strong>Physician expertise:</strong> Procedures are led by specialists like Dr. Ron Ram with 900+ transplant cases.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli centers like Sheba and Ichilov offer a significant logistical advantage through point-of-care manufacturing. While US clinics often ship cells to centralized labs, Israeli doctors engineer them on-site. This removes weeks of waiting. It also potentially lowers costs by up to _price_percent_discount_% compared to the US average of _price_compare_US_average_.</p> <p><strong>Patient Consensus:</strong> Many see this as a functional cure that keeps them cancer-free for years. Recovery usually spans one year and requires full re-vaccination to rebuild the altered immune system.</p>"},{"q":"Is CAR-T therapy used for autoimmune diseases in Israel?","a":"<p>Israeli institutions like Sheba Medical Center are world leaders in using CAR T-cell therapy for severe, treatment-resistant autoimmune diseases. Currently, this treatment is available primarily through clinical trials for conditions like systemic lupus erythematosus, scleroderma, and multiple sclerosis at specialized centers.</p> <ul> <li><strong>Target diseases:</strong> Specialized trials focus on lupus, scleroderma, rheumatoid arthritis, vasculitis, and myositis.</li> <li><strong>Clinical eligibility:</strong> Patients typically must have failed at least 2 or 3 standard treatments.</li> <li><strong>In-house manufacturing:</strong> Sheba Medical Center uses independent CAR-T production to accelerate patient access times.</li> <li><strong>Hospital duration:</strong> Most CAR-T protocols in Israel require a 21-day inpatient stay for monitoring.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While most clinics focus on oncology, Sheba Medical Center uniquely utilizes its own GMP-certified manufacturing facility to produce CAR-T cells on-site. This vertical integration allows them to modify protocols for autoimmune patients faster than centers relying on external pharma suppliers.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that while early results show drug-free remission, these therapies remain experimental for autoimmune issues. Most recommend verifying trial eligibility for specific biomarkers like B-cell markers before traveling.</p>"},{"q":"What makes Israel a leader in CAR T-cell therapy and what is the 'in-house' CAR-T program?","a":"<p>Israel leads in CAR T-cell therapy through vertical integration of research and treatment. Since Dr. Zelig Eshhar pioneered the technology in 1989, Israeli centers like Sheba and Sourasky have utilized on-site GMP labs to engineer personalized cells, ensuring rapid delivery and high success rates.</p> <ul> <li><strong>In-house production:</strong> Hospitals manufacture genetic therapies in local labs, bypassing expensive commercial shipping.</li> <li><strong>Treatment speed:</strong> Local engineering reduces wait times to 10 days, preventing disease progression.</li> <li><strong>Success rates:</strong> Clinical programs report up to 90% remission for resistant multiple myeloma cases.</li> <li><strong>Safety profile:</strong> Patient data indicates local protocols maintain high efficacy without typical neurotoxicity.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While commercial CAR-T can exceed $525,000, Israel's in-house programs provide high-tier care for _op_800_price_from_ to _op_800_price_to_. Doctors like Elad Jacoby at Sheba even integrate advanced pediatric protocols that aren't widely available yet, making it a hub for complex childhood relapses.</p> <p><strong>Patient Consensus:</strong> Patients value the speed of the homegrown program, often noting that local production removes the logistical stress of importing cells. Many report a safer recovery experience and high confidence in the foundational research performed by Israeli scientists.</p>"},{"q":"What types of cancer can be treated with CAR-T in Israel?","a":"<p>Israel treats several relapsed or refractory blood cancers with CAR T-cell therapy, specifically targeting leukemia, lymphoma, and multiple myeloma. Major JCI-accredited facilities like Sheba Medical Center and Sourasky Medical Center (Ichilov) also pioneer CAR-T applications for severe autoimmune diseases and Richter's transformation.</p> <ul> <li><strong>Leukemia types:</strong> Treats pediatric and adult acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL).</li> <li><strong>Lymphoma types:</strong> Includes diffuse large B-cell (DLBCL), follicular (FL), mantle cell, and Burkitt lymphoma.</li> <li><strong>Multiple myeloma:</strong> Available for patients who have relapsed after standard treatments like stem cell transplants.</li> <li><strong>Experimental applications:</strong> Clinics are researching CAR-T for severe lupus, rheumatoid arthritis, and primary CNS lymphoma.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Patient data shows a clear speed advantage at Sheba Medical Center due to their in-house, point-of-care manufacturing. While commercial CAR-T can take weeks to import, local production can reduce the time from collection to infusion to just 10 days.</p> <p><strong>Patient Consensus:</strong> Patients emphasize that this therapy is a vital last-line option for resistant cancers. They recommend consulting hematologists at major centers early to determine eligibility for `homegrown` Israeli protocols.</p>"},{"q":"What is included in the CAR T-cell treatment package?","a":"<p>CAR T-cell treatment packages in Israel include comprehensive medical services covering leukapheresis, genetic modification, lymphodepleting chemotherapy, and the final cellular infusion. These bundles also provide extensive 21-day hospitalization and 24-hour nursing care to monitor for cytokine release syndrome and neurotoxicity.</p> <ul> <li><strong>Medical evaluations:</strong> Packages include oncologist consultations, PET/CT scans, biopsies, and multidisciplinary eligibility screenings.</li> <li><strong>Cell manufacturing:</strong> Laboratory genetic engineering of patient T-cells is a core inclusion across centers.</li> <li><strong>Hospital stay:</strong> Most plans guarantee 21 days of inpatient care for intensive post-infusion monitoring.</li> <li><strong>Travel logistics:</strong> VIP airport-to-clinic transfers are standard, with some packages adding 7-14 hotel nights.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli centers like Sheba Medical Center offer a distinct advantage with in-house CAR-T manufacturing. This `Point-of-Care` model can reduce manufacturing time and total costs. While US prices average _price_compare_US_average_, Israeli programs offer similar success rates at _op_800_price_from_ to _op_800_price_to_.</p> <p><strong>Patient Consensus:</strong> Patients value the multidisciplinary evaluation that confirms eligibility before travel. Practical insights highlight the necessity of bridging therapy to manage tumor burden during the 2-week cell manufacturing phase.</p>"},{"q":"What are the steps of the CAR T-cell therapy process?","a":"<p>The CAR T-cell process involves extracting a patient's T-cells through leukapheresis, genetically engineering them to recognize cancer, and re-infusing them after lymphodepleting chemotherapy. This personalized immunotherapy typically requires a 30-day manufacturing window followed by 21 days of inpatient monitoring in specialized hematology departments.</p> <ul> <li><strong>Cell collection:</strong> Leukapheresis extracts white blood cells over 4 to 6 hours without anesthesia.</li> <li><strong>Genetic engineering:</strong> Specialized labs insert Chimeric Antigen Receptors (CAR) into T-cells using viral vectors.</li> <li><strong>Cell expansion:</strong> Scientists multiply engineered cells until reaching millions or billions for therapeutic potency.</li> <li><strong>Pre-conditioning:</strong> Brief chemotherapy clear space for new cells to expand and function effectively.</li> <li><strong>Inpatient stay:</strong> Patients remain hospitalized for 20 to 21 days to monitor for immune responses.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli centers like Sheba Medical Center offer a unique advantage through in-house Advanced Biotherapy Centers. While many global clinics wait for external logistics, these homegrown facilities can expedite point-of-care manufacturing for complex cases. This proximity is vital for high-risk patients who require immediate bridging therapy to remain stable during the cell-growth window.</p> <p><strong>Patient Consensus:</strong> Timing is critical because the 30-day manufacturing period requires patients to remain stable. Successful outcomes often depend on clearing strict health screens regarding heart, lung, and kidney function before eligibility confirms.</p>"},{"q":"Where can I find CAR T-cell clinical trials in Israel?","a":"<p>CAR T-cell clinical trials in Israel are conducted at major academic centers including Sheba Medical Center, Hadassah Medical Center, and Sourasky Medical Center. These JCI-accredited institutions host trials for relapsed blood cancers and autoimmune diseases, often utilizing in-house manufacturing to reduce wait times.</p> <ul> <li><strong>Sheba Medical Center:</strong> Features GMP-certified labs for point-of-care cell manufacturing within 10–11 days.</li> <li><strong>Hadassah Medical Center:</strong> Leads breakthrough trials specifically for multiple myeloma and resistant blood cancers.</li> <li><strong>Sourasky Medical Center:</strong> Conducts trials for advanced lymphomas under the leadership of triple board-certified experts.</li> <li><strong>Eligibility criteria:</strong> Most trials require patients to have failed 2 or 3 standard treatment lines.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli centers like Sheba and Sourasky are unique because they manufacture CAR-T cells in-house rather than shipping samples to external pharmaceutical labs. This approach typically cuts the typical 4-week waiting period by half. For international patients, this speed is critical as it reduces the risk of disease progression while the cells are being engineered.</p> <p><strong>Patient Consensus:</strong> Patients value these trials for high safety standards, with many noting a significant lack of serious neurotoxicity side effects. Navigating the qualification process usually requires recent bone marrow biopsy results and a history of previous therapy failures.</p>"},{"q":"Why is Israel a top destination for neurosurgery?","a":"<p>Israel is a premier neurosurgery hub due to its fusion of high-density medical innovation and elite surgical expertise. Top facilities like Sheba Medical Center integrate AI-guided navigation and real-time intraoperative MRI. Specialized centers report 98% success rates for complex procedures including awake craniotomy and movement disorder treatments.</p> <ul> <li><strong>Advanced technology:</strong> Clinics utilize MRI-guided focused ultrasound (MRgFUS) and robotic systems for incisions.</li> <li><strong>Surgical expertise:</strong> Surgeons like Dr. Zvi Ram lead international associations with 25+ years experience.</li> <li><strong>Rapid access:</strong> International patients typically schedule complex brain or spine surgeries within 2–4 weeks.</li> <li><strong>Accredited care:</strong> Major centers like Sourasky (Ichilov) and Assuta hold JCI accreditation for safety.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data shows a clear divide between public and private options in Israel. Private centers like Assuta Medical Center perform over 92,000 operations annually and allow patients to select their specific lead surgeon. This is a vital advantage for complex cases where a specific expert like Dr. Eli Ashkenazi is preferred for his 1,000+ spine surgery record.</p> <p><strong>Patient Consensus:</strong> Patients emphasize bringing original imaging on a USB for local review to streamline the surgical plan. They also note that private packages often include hotel coordination and airport transfers, making the logistics much smoother.</p>"},{"q":"What types of neurosurgical conditions are treated in Israel?","a":"<p>Israeli neurosurgeons treat a full spectrum of conditions ranging from brain and spinal tumors to complex functional disorders. Specialized centers utilize advanced technologies like Gamma Knife, deep brain stimulation, and intraoperative MRI to manage epilepsy, Parkinson disease, and cerebrovascular pathologies with high precision.</p> <ul> <li><strong>Oncological conditions:</strong> Treatment for gliomas, meningiomas, and pituitary tumors using skull base resection.</li> <li><strong>Functional disorders:</strong> Management of Parkinson disease and essential tremors via deep brain stimulation.</li> <li><strong>Spinal pathologies:</strong> Correction of scoliosis, herniated discs, and spinal tumors using robotic systems.</li> <li><strong>Cerebrovascular care:</strong> Surgical repair of brain aneurysms and arteriovenous malformations with endovascular interventions.</li> <li><strong>Pediatric neurosurgery:</strong> Specialized care for hydrocephalus and congenital anomalies at dedicated children centers.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli hospitals often combine specialties to handle complex cases. At Sourasky Medical Center, neurosurgeons like Dr. Zvi Lidar bridge neurosurgery and orthopedics for spinal care. This multidisciplinary approach allows clinics to perform 34,000+ operations annually. Choosing a facility with this crossover expertise often leads to more comprehensive treatment plans for degenerative diseases.</p> <p><strong>Patient Consensus:</strong> Patients value the ability to access specialized treatments like fluorescence-guided surgery for tumors which are often unavailable elsewhere. Many note that the staff is fluent in English and provides clear communication through teleconsultations before traveling.</p>"},{"q":"Which hospitals in Israel are best known for neurosurgery?","a":"<p>Israel is home to world-renowned neurosurgery centers like Sourasky Medical Center, Sheba Medical Center, and Hadassah Medical Center. These facilities are globally ranked for treating complex brain tumors, spinal disorders, and movement diseases. They utilize advanced technologies like Gamma Knife, robotic systems, and intra-operative MRI.</p> <ul> <li><strong>Sourasky (Ichilov):</strong> Performs 2,500+ neurosurgical operations yearly with a 98% success rate in Tel Aviv.</li> <li><strong>Sheba Medical Center:</strong> Ranked among the world's top 10 hospitals. It treats 1.9 million patients annually.</li> <li><strong>Hadassah Medical Center:</strong> A Nobel Peace Prize nominee. It leads in pediatric neurosurgery and gene-based therapies.</li> <li><strong>Assuta Medical Center:</strong> Israel's largest private facility. It specializes in minimally invasive spine and brain surgeries.</li> <li><strong>Schneider Children's:</strong> The primary center for pediatric neurosurgery. It treats 275,000 children every year.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Our data shows that while most patients focus on Tel Aviv, Rambam Medical Center in Haifa offers unique expertise in neuro-trauma. It operates a specialized neuro-ICU and serves nearly 1 million patients annually. This makes it an essential choice for complex post-trauma brain surgeries that requires intensive recovery support.</p> <p><strong>Patient Consensus:</strong> Patients note it is important to start consultations early. They often highlight that the precision and follow-up care for complex brain tumors exceeded their expectations. One patient emphasized how quickly they could connect with top professors for second opinions during critical neurosurgical cases.</p>"},{"q":"Who are Israel’s leading neurosurgeons?","a":"<p>Israel's leading neurosurgeons include Prof. Zvi Ram, Prof. Shlomi Constantini, and Prof. Itzhak Fried at Sourasky Medical Center. These specialists hold leadership roles in the European Association of Neurosurgical Societies (EANS) and the World Society for Stereotactic and Functional Neurosurgery (WSSFN). They utilize advanced intraoperative mapping and robotic systems.</p> <ul> <li><strong>Prof. Zvi Ram:</strong> Expert in minimally invasive brain tumor surgery and gene-based oncology therapies.</li> <li><strong>Prof. Shlomi Constantini:</strong> Specializes in complex pediatric neuro-endoscopy and brain tumor microsurgery.</li> <li><strong>Prof. Itzhak Fried:</strong> Authority on epilepsy surgery, functional brain mapping, and deep brain stimulation.</li> <li><strong>Dr. Eli Ashkenazi:</strong> Leading spine surgeon at Assuta, specializing in the innovative TOPS system.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data from Sourasky and Sheba indicates a strong correlation between high surgical volumes and patient safety. For example, Sourasky performs 34,000+ operations annually with a 90% oncology success rate. Patients seeking complex tumor removals should prioritize centers like these where surgeons perform hundreds of specific cases each year.</p> <p><strong>Patient Consensus:</strong> Patients emphasize the importance of finding a surgeon who specializes specifically in your condition rather than a generalist. Many note that high-volume centers provide better access to English-speaking staff and coordinated care for international visitors.</p>"},{"q":"What are the admission requirements for international neurosurgery patients?","a":"<p>International neurosurgery patients in Israel must provide comprehensive medical records including recent MRI or CT scans translated into English. Admission requires a clinical review by specialists to confirm treatment feasibility. Hospitals often mandate full advance payment or a significant deposit before confirming surgery dates or issuing visa support letters.</p> <ul> <li><strong>Medical documentation:</strong> Submit detailed English-translated reports and imaging for clinical review within 48 hours.</li> <li><strong>Financial clearance:</strong> Provide proof of funds for approximately _price_from_ to _price_to_ for treatment.</li> <li><strong>Visa support:</strong> Clinics like Sourasky Medical Center (Ichilov) issue official letters for medical B-2 visas.</li> <li><strong>Consultation phase:</strong> Initial assessment often occurs via online consultation with surgeons like Dr. Strauss Ido.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data shows that top Israeli facilities like Sheba Medical Center and Hadassah Medical Center handle massive patient volumes, exceeding 1,000,000 people annually. This high demand means clinics prioritize complex or rare cases over routine procedures. Patients with unique or high-risk conditions often receive faster admission approval than those seeking standard treatments available elsewhere.</p> <p><strong>Patient Consensus:</strong> Patients note that having all imaging results ready in English is essential for quick scheduling. Many emphasize that while the medical care is excellent, coordinating around Shabbat closures is necessary to avoid unexpected diagnostic delays.</p>"},{"q":"How long will I need to stay in Israel for neurosurgery and follow-up?","a":"<p>A standard stay for neurosurgery in Israel ranges from 10 to 14 days for uncomplicated cases. Patients undergoing complex procedures like brain tumor removal or deep brain stimulation often require 4 to 6 weeks. This timeline covers pre-operative diagnostics, the surgical procedure, and essential post-operative monitoring.</p> <ul> <li><strong>Hospitalization duration:</strong> Minimally invasive procedures require 1–3 days. Regular craniotomies average 3–10 days.</li> <li><strong>Local recovery:</strong> Stay in Israel for 7–14 days post-discharge for mandatory follow-up checks.</li> <li><strong>Flight safety:</strong> Surgeons recommend waiting 4–6 weeks before flying to stabilize internal head pressure.</li> <li><strong>Follow-up schedule:</strong> In-person clinical reviews typically occur at days 3, 7, and 14 post-surgery.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data from Sourasky Medical Center shows they treat over 400,000 patients annually with high success rates. Clinics with such high volumes, like Hadassah or Assuta, often have streamlined discharge protocols. This helps international patients transition to hotel-based recovery faster while maintaining access to top specialists.</p> <p><strong>Patient Consensus:</strong> Patients note it is vital not to rush home too early. Some travelers extended their stay to 3 weeks due to swelling or to ensure they received final surgeon clearance before flying.</p>"},{"q":"What advanced technologies make Israeli neurosurgery minimally invasive?","a":"<p>Israeli neurosurgery uses robotic guidance, real-time 3D imaging, and incisionless technologies to minimize physical trauma. Systems like Mazor Robotics provide sub-millimeter precision for spine implants. MRI-guided focused ultrasound (MRgFUS) treats tremors without incisions. These advanced tools ensure high accuracy and reduce recovery times.</p> <ul> <li><strong>Robotic systems:</strong> Mazor and ROSA robotics enable precise instrument placement through tiny incisions.</li> <li><strong>Incisionless ultrasound:</strong> MRgFUS uses high-intensity sound waves to treat brain tissue without anesthesia.</li> <li><strong>Digital navigation:</strong> Intraoperative MRI and 3D mapping allow surgeons to verify results in real-time.</li> <li><strong>Advanced endoscopy:</strong> Transnasal and trans-orbital approaches remove tumors without traditional skull-opening craniotomies.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli clinics like Sourasky or Hadassah integrate proprietary Israeli-born technologies like Surgical Theater before they hit global markets. Our data shows these centers often use VR flight-through models for pre-surgical planning. This allows surgeons to rehearse complex cases, which is a key factor in their 90% success rates.</p> <p><strong>Patient Consensus:</strong> Patients note that technologies like the Gamma Knife allowed them to return home in days rather than weeks. Many move from traditional 10cm incisions to cuts under 2cm when using robotic-assisted systems.</p>"},{"q":"Why is Israel considered a top destination for neurosurgery?","a":"<p>Israel is a global leader in neurosurgery due to its integration of proprietary medical innovations and internationally trained specialists. High-capacity centers like Sourasky Medical Center (Ichilov) perform over 34,000 annual surgeries. Patients access advanced techniques like awake craniotomy and MR-guided focused ultrasound.</p> <ul> <li><strong>Advanced technology:</strong> Facilities use CyberKnife, Gamma Knife, and robotic systems for precision.</li> <li><strong>Expert credentials:</strong> Specialists like Dr. Zvi Ram hold leadership roles in European neurosurgical societies.</li> <li><strong>Global training:</strong> Most senior neurosurgeons completed fellowships at premier United States and European institutions.</li> <li><strong>Specialized departments:</strong> Centers feature niche units for pediatric neurosurgery, skull base, and functional disorders.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli neurosurgery stands out because of the high concentration of dually certified experts. Many top surgeons, such as Dr. Zvi Lidar, are certified to practice in both Israel and the USA. This ensures that patients receive American-standard surgical care while staying in Tel Aviv or Jerusalem. Our data shows that private centers like Assuta offer significantly faster access to these specific specialists compared to the public system.</p> <p><strong>Patient Consensus:</strong> Patients note it is important to confirm a surgeon's specific volume of cases for your exact condition. They also value the ability to get expert second opinions quickly through online consultations with world-renowned professors.</p>"},{"q":"Which hospitals are ranked among the best for neurosurgery in Israel?","a":"<p>Sheba Medical Center and Sourasky Medical Center (Ichilov) are among the best neurosurgery hospitals in Israel. These JCI-accredited facilities perform thousands of operations annually. They utilize advanced technologies like CyberKnife and intraoperative MRI to treat complex brain tumors and cerebrovascular lesions.</p> <ul> <li><strong>Sheba Medical Center:</strong> Ranked among the top 10 world hospitals by Newsweek magazine.</li> <li><strong>Sourasky (Ichilov):</strong> Reports a 98% success rate and performs 2,500+ neurosurgical operations annually.</li> <li><strong>Hadassah Medical Center:</strong> Known for pioneering endoscopic techniques and integrated advanced research programs.</li> <li><strong>Assuta Medical Center:</strong> Israel largest private facility specializing in minimally invasive spine procedures.</li> <li><strong>Rambam Medical Center:</strong> Employs Nobel Prize laureates and serves as a major referral center.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Our data shows that top Israeli centers like Sourasky and Hadassah perform over 40,000 total operations yearly. This high volume allows surgeons to maintain a 90% success rate even in complex oncology cases. Patients seeking robotic spine surgery or deep brain stimulation should focus on these high-capacity municipal centers for the most experienced teams.</p> <p><strong>Patient Consensus:</strong> Patients appreciate that some hospitals quickly coordinate consultations even during regional strikes. Families of pediatric patients especially value surgeons trained at prestigious international institutions.</p>"},{"q":"Who are the leading neurosurgeons in Israel?","a":"<p>Israel's leading neurosurgeons include Professor Zvi Ram, Professor Shlomi Constantini, and Professor Itzhak Fried at Sourasky Medical Center. These experts specialize in awake craniotomy, pediatric brain tumors, and functional mapping. Most hold JCI accreditation and international fellowships from institutions like Johns Hopkins and Yale.</p> <ul> <li><strong>Brain tumors:</strong> Professor Zvi Ram specializes in image-guided microsurgery and complex brain mapping techniques.</li> <li><strong>Pediatric expertise:</strong> Professor Shlomi Constantini leads pediatric neurosurgery, focusing on endoscopic treatments and malformations.</li> <li><strong>Functional surgery:</strong> Professor Itzhak Fried is a global authority on epilepsy and deep brain stimulation.</li> <li><strong>Spine specialists:</strong> Dr. Zvi Lidar and Dr. Eli Ashkenazi focus on minimally invasive spinal oncology.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data shows that top-tier Israeli neurosurgeons, such as those at Sourasky Medical Center, often hold dual board certifications in Israel and the US. This unique crossover ensures patients receive American-standard protocols. These specialists typically manage over 34,000 annual operations, providing high-volume clinical experience that smaller private clinics cannot match.</p> <p><strong>Patient Consensus:</strong> Patients note that highly qualified doctors like Professor Shlomo Constantini provide satisfactory answers quickly. People emphasize that outcomes often depend on the hospital’s integrated resources rather than just a doctor's prestige.</p>"},{"q":"What neurosurgical conditions and sub-specialties are treated in Israel?","a":"<p>Israel is a global leader in neurosurgery, treating complex brain and spinal conditions using robotic-assisted and minimally invasive techniques. Highly specialized units at JCI-accredited centers like Sourasky Medical Center (Ichilov) and Hadassah Medical Center focus on neuro-oncology, pediatric neurosurgery, and functional procedures.</p> <ul> <li><strong>Neuro-oncology:</strong> Treating glioblastoma, meningioma, and skull base tumors with 90% success rates.</li> <li><strong>Functional neurosurgery:</strong> Performing deep brain stimulation (DBS) for Parkinson’s and drug-resistant epilepsy.</li> <li><strong>Pediatric specialty:</strong> Specialized care for congenital defects and childhood tumors at Schneider Children’s.</li> <li><strong>Spine surgery:</strong> Utilizing Mazor X robotic systems for scoliosis and herniated disc correction.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Israeli neurosurgical departments often function as rapid-response hubs for international patients. Data shows that large centers like Sourasky, which serves 1,800,000 patients annually, can organize expert video consultations in a very short time. This speed is critical for neuro-oncology cases where starting treatment a few days earlier significantly impacts outcomes.</p> <p><strong>Patient Consensus:</strong> Patients note that Israeli teams often accept high-risk cases that other hospitals decline. They emphasize the importance of using local coordinators to manage travel logistics or potential local disruptions during their two-week stay.</p>"},{"q":"What documentation do international patients need before traveling to Israel for neurosurgery?","a":"<p>International patients traveling to Israel for neurosurgery require a valid passport, an entry permit or medical visa, and a formal hospital invitation. You must provide recent MRI or CT scans in DICOM format and detailed medical summaries. Proof of private health insurance and financial stability are also mandatory for border entry.</p> <ul> <li><strong>Travel authorization:</strong> Most visa-exempt travelers now need an approved ETA-IL before departure.</li> <li><strong>Hospital invitation:</strong> A signed letter from facilities like Sourasky Medical Center is required.</li> <li><strong>Medical records:</strong> Provide updated summaries of diagnoses, medications, and previous neurological treatments.</li> <li><strong>Imaging files:</strong> Digital copies of scans are essential for planning complex brain surgeries.</li> <li><strong>Legal consent:</strong> Notarized power of attorney is required for patients under 18 years old.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Our data shows that top neurosurgeons at Hadassah Medical Center and Sourasky often request records 4–6 weeks before arrival. Submitting these early prevents appointment shifts. High-volume centers with over 30,000 annual operations have dedicated portals for secure DICOM file uploads. Using these ensures your surgeon reviews high-quality images before you land in Tel Aviv.</p> <p><strong>Patient Consensus:</strong> Patients emphasize bringing physical copies and digital backups of all scans on a USB drive. They also note that private insurance needs pre-authorization specifically for neurosurgery to avoid payment delays at the clinic.</p>"}],"h2":[{"text":"Come funziona","kind":"content"},{"text":"Qual è il prezzo di Terapia con cellule CAR-T in Israele? Scoprilo ora","kind":"content"},{"text":"Non perdere queste offerte esclusive di Terapia con cellule CAR-T in Israele per novembre 2026","kind":"content"},{"text":"Scopri le migliori cliniche di Terapia con cellule CAR-T in Israele: 13 opzioni verificate e Prezzi","kind":"content"},{"text":"Panoramica di Terapia con cellule CAR-T in Israele","kind":"content"},{"text":"Ottieni una valutazione medica di Terapia con cellule CAR-T in Israele: consulta ora 16 medici esperti","kind":"content"},{"text":"Recensioni","kind":"content"},{"text":"Condividi contenuto","kind":"content"},{"text":"Storie in video dei pazienti Bookimed","kind":"content"},{"text":"Tutto ciò che devi sapere su Terapia con cellule CAR-T in Israele","kind":"content"},{"text":"Che cos'è la terapia con cellule CAR-T?","kind":"content"},{"text":"Quale tecnica è più adatta alle tue esigenze?","kind":"content"},{"text":"Chi è un candidato per la terapia con cellule CAR-T?","kind":"content"},{"text":"Come viene eseguita la terapia con cellule CAR-T?","kind":"content"},{"text":"Cosa succede durante il percorso di recupero?","kind":"content"},{"text":"Quali sono i rischi e le possibili complicazioni?","kind":"content"},{"text":"Risultati: quando aspettarsi un effetto?","kind":"content"},{"text":"Perché scegliere la terapia con cellule CAR-T in Israele?","kind":"content"},{"text":"Cosa sapere prima di sottoporsi alla terapia con cellule CAR-T in Israele?","kind":"content"},{"text":"Qual è il costo della terapia con cellule CAR-T in Israele?","kind":"content"},{"text":"Pacchetti di terapia con cellule CAR-T in Israele","kind":"content"},{"text":"Riferimenti","kind":"content"},{"text":"Domande frequenti su Terapia con cellule CAR-T in Israele","kind":"content"},{"text":"Richiedi una consulenza gratuita","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}